US20030124194A1 - Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor - Google Patents
Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor Download PDFInfo
- Publication number
- US20030124194A1 US20030124194A1 US10/335,790 US33579003A US2003124194A1 US 20030124194 A1 US20030124194 A1 US 20030124194A1 US 33579003 A US33579003 A US 33579003A US 2003124194 A1 US2003124194 A1 US 2003124194A1
- Authority
- US
- United States
- Prior art keywords
- nanoparticle
- polymer
- carboxyl groups
- magnetic
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention relates to novel superparamagnetic nanoparticle compositions, synthesis and uses thereof.
- Carboxyl bearing polymers have found a wide usage in food, drugs, and industrial applications.
- a few well known examples include the carboxymethyl (‘CM’) polysaccharides CM-cellulose, CM-dextran, and CM-arabinogalactan (U.S. Pat. No. 5,981,507).
- the CM polysaccharides are produced from a reaction of the polysaccharide with haloacetic acids in base.
- Carboxyl bearing polymers have been used in the synthesis of magnetic nanoparticles.
- Carboxylated dextrans of two major types have been used in the synthesis of superparamagnetic iron oxide nanoparticles.
- Carboxydextrans have a single terminal carboxyl group on each dextran molecule obtained by treatment with base (Hasegawa U.S. Pat. No. 4,101,435; Hasegawa U.S. Pat. No. 5,424,419, column 2, line 17).
- Carboxymethylated dextrans have numerous carboxymethyl groups attached per mole of dextran by reaction of alkyl halogenated acids in base (Maruno U.S. Pat. No. 5 , 204 , 457 ; Groman WO 00/61191).
- Magnetic nanoparaticles used for the attachment of biomolecules have been described by Molday (U.S. Pat. No. 4,452,773).
- a dextran coated magnetic nanoparticle is formed and then treated with periodate to produce aldehyde groups.
- the aldehydes react with amino groups on a biological molecule, to form a Schiff base.
- the Schiff base maybe stabilized by treatment of with a reducing agent like sodium borohydride.
- a methylene amino linker connects the biomolecule to the nanoparticle.
- FIG. 2B there are no peptidyl bonds in such linkages.
- a drawback of this method is the difficulty controlling the number and position of amino groups on the biomolecule that are available to react with the reactive aldehyde groups on the nanoparticle.
- Amino-CLIO amine functionalized crosslinked iron oxide nanoparticle
- FIG. 2 The development of amine functionalized crosslinked iron oxide nanoparticle (“amino-CLIO”, FIG. 2) by one of the inventors has proven to be an excellent method of synthesizing magnetic particle-biomolecule conjugates.
- Amino-CLIO is prepared by first synthesizing a dextran coated magnetic nanoparticle, followed by crosslinking the dextran with epichlorohydrin. Finally the amine groups are incorporated by reacting the dextran with ammonia (see Josephson et al, (1999) Bioconjug Chem 10, 186-91; Josephson et. al (2001) Angwandte Chemie 40, 3204-3206;).
- Amino-CLIO is an excellent label for the attachment of biomolecules, and for the synthesis of magnetic nanoparticle-biomolecule conjugates, for two reasons.
- bifunctional conjugating reagents are SPDP, SIA, SMCC and MBS. These reagents are available commercially (Pierce Chemical or Molecular Biosciences).
- amino-CLIO examples include peptides (Josephson et al, (1999) Bioconjug Chem 10, 186-91), oligonucleotides (Josephson et. al (2001) Angwandte Chemie 40, 3204-3206;) and proteins (Hogemann et al. (2000). Bioconjug Chem 11, 941-6).
- amino-CLIO is highly stable due to the fact that the crosslinking forms a shell of dextran around a core of iron oxide. This allows storage of either amino-CLIO or bioconjugates based on amino-CLIO under a wide range of conditions (temperature, pH, ionic strength). By covalently joining polymeric molecules of the coating, crosslinking is associated with a pronounced increase in the molecular weight of the polymeric coating.
- This amino-CLIO based chemistry has one major drawback, however, which arises precisely because of the extraordinary stability achieved by using a crosslinked-stablilized dextran on the nanoparticle surface.
- a crosslinked-stablilized dextran on the nanoparticle surface.
- the degradation or elimination of the agent, including the coating is required.
- the iron oxide of an amino-CLIO based MR contrast is dissolved or biodegraded, the crosslinked dextran remains as a non-degradable sphere of polysaccharide.
- non-degradability occurs with micron-sized magnetic microspheres where iron oxide is entrapped in a non-biodegradable polymeric shell (see U.S. Pat. Nos. 4,654,267; 5,512,439).
- CM-polymers can also function as starting materials for the synthesis of drugs conjugates or for the attachment of various biological molecules.
- drug conjugates CM-arabinogalactan, CM-dextran and polyvinyl alcohol were used as carriers for nucleotide analogues (U.S. Pat. No. 5,981,507).
- the carboxyl groups were converted to primary amino groups by reaction with diamines.
- Biological molecules like araAMP were then attached to the primary amine of the aminated arabinogalactan, see Josephson, et al. (1996) Antivir Ther 1, 147-56 and U.S. Pat. No. 5,478,576.
- CM-polymers such as CM-arabinogalactan
- CM-arabinogalactan exist as macromolecules in solution, which allows conditions to be employed that insure the nearly quantitative conversion of carboxyl groups to amino groups.
- the absence of protected carboxyl groups allows essentially all carboxyl groups to be chemically reactive.
- the present invention relates to aminofunctionalzied nanoparticles.
- the nanoparticles have a magnetic core having one or more magnetic metal oxide crystals, and a noncrosslinked polymer coating associated with the core.
- the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups. A portion of the carboxyl groups are associated with the crystals.
- a portion of the amino groups are associated with polymer through a peptidyl linkage of the formula:
- X is —(CH 2 ) n NH 2 , —(CH 2 ) o CH NHCOO—, —(CH 2 ) 3 NH(CH 2 ) 4 NH 2 or —(CH 2 ) 3 NH(CH 2 ) 4 NH(CH 2 ) 3 NH 2 —
- the magnetic core has one or more superparamagnetic iron oxide crystals.
- the superparamagnetic core has a diameter between about 1 nm and about 25 nm, preferably between about 3 nm and about 10 nm, and more preferably about 5 nm.
- the nanoparticle (core and polymer) has diameter between about 15 nm and 100 nm, preferably between about 20 nm and about 100 nm.
- the polymer coating may be made from natural polymers, or synthetic polymers, or derivatives or each.
- Nonlimiting examples include polyvinyl alcohol and carboxymethyldextran
- the nanoparticle can be conjugated to a biomolecule.
- a nanoparticle biomolecule conjugate in another aspect of the invention, there is provided a nanoparticle biomolecule conjugate.
- the nanoparticle portion includes a magnetic core having one or more magnetic metal oxide crystals, a noncrosslinked polymer coating associated with the core.
- the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups. A portion of the carboxyl groups are associated with the crystals, In one embodiment, the amino groups are associated with polymer through a peptidyl linkage of the formula:
- X is —(CH 2 ) n NH 2 , —(CH 2 ) o CH NHCOO—, —(CH 2 ) 3 NH(CH 2 ) 4 NH 2 or —(CH 2 ) 3 NH(CH 2 ) 4 NH(CH 2 ) 3 NH 2 —
- a process for synthesizing an amine functionalized magnetic metal oxide nanoparticle via the steps of (i) obtaining a polymer having a plurality of carboxyl groups attached thereto, (ii) contacting the polymer with magnetic metal oxide to produce a coated magnetic metal oxide wherein a portion of said carboxyl groups are associated with the metal oxide; and (iii) reacting the coated magnetic metal oxide of step (ii) with a diamine.
- the diamine is ethylene diamine; in another embodiment the diamine is hexane diamine.
- the contacting step in the synthesis further includes the steps of (a) providing a solution of soluble iron salts; (b) converting the iron salts into iron oxide crystals; and (c) removing unassociated polymer.
- the converting process includes the further steps of (a) heating the iron salts to a temperature between about 4° C. and about 20° C.; and adding an amount of base to raise the pH to about 8 or higher to form iron oxides.
- the process includes the step of heating the iron oxides to a temperature about 60° C. or more for at least 30 minutes.
- Another aspect of the invention provides a pharmaceutical composition of the nanoparticle biomolecule conjugates and a pharmaceutically acceptable carrier. This composition is particularly useful in targeted MR imaging applications.
- the large sphere represents the core magnetic material.
- FIG. 1 shows a reaction scheme for synthesis of amino functionalized magnetic nanoparticles.
- a polymer 1 having multiple carboxyl groups is obtained.
- the polymer is used to synthesize a coated nanoparticle.
- the core magnetic material is shown as a dark sphere 2 .
- Carboxyl groups face (i) both the magnetic core which are blocked (arrow 3 b ) and (ii) the solvent (arrow 3 a ) and are available for further reaction.
- the free carboxyl groups are reacted, here with carbodiimide, to produce the amine functionalized nanoparticle 4 .
- FIGS. 2 A-C are comparisons of the prior art nanoparticles (FIGS. 2A and 2B) with the nanoparticles of the invention ( 2 C).
- the prior art nanoparticles use crosslinked dextran and ammonia. This produces a functionalized particle in which every nitrogen is a primary amine.
- the polymer is associated with the magnetic core (large sphere) via hydroxyl groups.
- the prior art nanoparticles use non-crosslinked dextran which has been reacted with periodate to form aldehydes, followed with EDA and a reducing agent.
- EDA electrospray dextran
- the polymer is associated with the magnetic core (large sphere) via hydroxyl groups.
- FIG. 2C shows the nanoparticles of the present invention.
- the polymer is noncrosslinked, and the amino group is linked to the polymer via a peptide bond. There are two nitrogen atoms for each primary amine: terminal amine 1 and at peptidyl linkage 2 .
- the noncrosslinked polymer is associated with the magnetic core (large sphere) via carboxyl groups.
- the present invention meets the aforementioned requirements by providing novel compositions of amino functionalized nanoparticles, and their methods of synthesis. These novel amino functionalized nanoparticles can serve further as magnetic nanoparticles for the development biomolecule-magnetic nanoparticle conjugates useful in a variety of in vitro, and in vivo applications.
- a nanoparticle as described and claimed herein is a material with a “core” of magnetic material associated with a polyfunctional noncrosslinked polymer.
- the polymer coating displays a plurality of carboxyl groups and reactive primary amino groups; a portion of the carboxyl groups are associated with the magnetic core; the reactive primary amino groups are available for subsequent covalent reactions, e.g., for the attachment of biomolecules.
- the nanoparticles have an overall size less than about 100 nm, before conjugation to biomolecules.
- the overall size of the nanoparticles is about 15 to 100 nm, preferably about 20 to 100 nm, more preferably about 40 to 60 nm; about 50 nm is the most preferred.
- the polymeric coating can be about 5 to 20 nm thick or more. Size can be determined by laser light scattering by atomic force microscopy or other suitable techniques.
- the nanoparticle core can be monodisperse (a single crystal of a magnetic material, e.g., metal oxide, such as superparamagnetic iron oxide, per particle) or polydisperse (a plurality of crystals, e.g., 2, 3, or 4, per particle).
- the metal oxides are crystals of about 1-25 nm, preferably about 3-10 nm, and most preferably about 5 nm in diameter.
- the magnetic metal oxide can also comprise cobalt, magnesium, zinc, or mixtures of these metals with iron.
- magnetic as used in this specification and the accompanying claims means materials of high positive magnetic susceptibility.
- a superparamagnetic form of iron oxide is used.
- Superparamagnetic iron oxide is one of the highly magnetic forms (magnetite, non-stoichiometric magnetite, gamma-ferric oxide) that has a magnetic moment of greater than about 30 EMU/gm Fe at 0.5 Tesla and about 300 K. When magnetic moment is measured over a range of field strengths, it shows magnetic saturation at high fields and lacks magnetic remanence when the field is removed.
- the “polymer coating” is a natural or synthetic polymer associated with the magnetic core that functions to keep the metal oxides dispersed from each other.
- the polymer “coating” is not a continuous film around the magnetic metal oxide, but is a “mesh” or “cloud” of extended polymer chains attached to and surrounding the metal oxide.
- the polymer coating may be a natural polymer, a synthetic polymer.
- the polymer maybe linear, or moderately or highly branched.
- the polymer coating can be carboxy dendrimers, commercially available from Sigma-Aldrich, which are highly branched polycarboxyl polymers. Other embodiments of the polymer coating are described in detail below.
- a natural polymer is obtained when a pure polymer, such as a polysaccharide, is synthesized by a microorganism, plant or animal and extracted in substantially pure form.
- natural polymers include polysaccharides, such as dextran.
- a synthetic polymer is obtained from nonbiological syntheses, by using standard polymer chemistry techniques known to those in the art to react monomers into polymers.
- the polymers may be homopolymers, i.e, synthesized from a single type of monomer, or co-polymers, i.e., synthesized from two or more types of monomers.
- Non-limiting examples of synthetic polymers include polymethylmethacrylate polymers and polyvinyl alcohol polymers.
- a crosslinked polymer is one in which functional groups on a polymer chain and/or branches has reacted with functional groups on another polymer to form polymer networks.
- Crosslinked polymers are characterized herein as being heat stable and resistant to breakdown in biological systems.
- a crosslinked polymer has a molecular weight significantly higher than the original starting polymer.
- a non-crosslinked polymer is described and claimed herein as a polymer in which few or no individual polymer chains have reacted with the functional groups of another polymer chain to form the interconnected polymer networks.
- a non-crosslinked polymer that has been functionalized is reasonably size homogeneous as compared to the starting polymer, i.e., the polymer before and after incorporation of amine and carboxyl functional groups have similar molecular weights and molecular weight distributions.
- a small increase in molecular weight of the polymer is seen generally as a result of the incorporation of functional groups onto the polymer and the few crosslinks that may occur on a statistical basis.
- a polycarboxyl (or carboxyl) polymer is a polymer with more than one carboxyl group per polymer.
- a polyfunctionalpolymer is one with different functional groups, such as amino and carboxyl groups attached to a polymer.
- amino functionalized nanparticles can be synthesized using non crosslinked, carboxylated polymers, and that these polymers permit the addition of reactive primary amine groups to the polymer. These reactive primary amines are attached to the polymer via peptidyl linkages.
- the resulting polymer coated nanoparticle has two classes of carboxyl groups with very different chemical reactivities. Some carboxyl groups are shielded from further chemical reaction by forming a strong bond between the polymer and the surface of the iron oxide. Some surface carboxyl groups, facing the bulk solvent, can be activated with carbodiimide and converted to reactive primary amino groups (FIG. 1). These reactive primary amines can be reacted with bifunctional conjugating agents and then with biomolecules to form targeted MR contrast agents, or probes for used in biosensors.
- the process for synthesizing magnetic nanoparticies involves three general steps: (i) obtaining a polycarboxylated polymer; (ii) synthesizing a polycarboxylated coated magnetic nanoparticle; and (iii) converting the surface carboxyl groups to reactive primary amine groups while the remaining carboxyl groups bind the polymer to the nanoparticle (FIG. 1).
- the magnetic nanoparticles of the invention have polyfunctional polymeric coating, i.e. one that contains both amino and carboxyl groups. Since the carboxylated polymer used to synthesize the magnetic nanoparticle in step (ii) possesses only a single class of carboxyl groups, it is highly surprising that the resulting polymer coated magnetic nanoparticle consists of two distinct types of carboxyl groups. One type is bound to the surface of the iron oxide (blocked from further chemical reaction). A second type is exposed to the bulk solvent and available for conversion to reactive primary amino groups, see FIG. 1. Moreover, the chemistry used to incorporate the functional groups results in a polymer coating that is noncrosslinked (i.e, uncrosslinked or minimnally crosslinked).
- interchain cross-linking can be induced in proteins, which present a mixture of amino and carboxyl groups on the surface, by activating agents like carbodiimide and is used to make aggregates of soluble proteins. For this reason the synthesis of polymers such as peptides containing amino and carboxyl groups requires use of protecting groups followed by deprotection. The synthesis used here eliminates the protection-deprotection reaction steps.
- Another feature of the amine functionalized nanoparticles of the invention is that they can be readily degraded to yield their metal salts and polymer coating.
- the degradation yields iron salts and the polyfunctional polymeric coating.
- this results in the utilization of iron oxide, by incorporation of iron into red blood cells, and by the excretion and/or degradation of the polycarboxylated polymer.
- the conditions of biodegradation can be simulated by exposing nanoparticles to mildly acidic pH (3-6) in the presence of a metal chelator, e.g. citrate or EDTA. This yields ferric ion chelates and soluble polyfunctional polymers.
- the molecular weight of the polyfunctional polymers, bearing amino and carboxyl groups, will be slightly larger than the polycarboxylated polymers used to synthesize the nanoparticles due the addition of reactive primary amino groups.
- the amine functionalized nanoparticles of the invention are synthesized by activation of free carboxyl groups of the nanoparticle with a water soluble carbodiimide, followed by reaction with a large excess of a diamine.
- the nature of the diamine provides a linker arm of varying lengths and chemistries for the attachment of biomolecules.
- diamines include ethylenediamine (EDA), propyldiamine, spermidine, spermine, hexanediamine, and diamine amino acids, such as lysine or omithine.
- ammonia is not used to make the amine functionalized nanoparticles of the invention.
- dextran coated magnetic nanoparticles are reacted with epichlorohydrin, followed by reaction with ammonia.
- This reaction produces a dextran crosslinked, amine functionalized nanoparticle bearing primary amino groups (H 2 N—CH 2 —CHOH—CH 2 —O-Polymer), as shown in FIG. 2A.
- an amide would be obtained (H 2 N—CO—CH 2 —O-Polymer).
- the nitrogen atoms of amides are far less reactive than primary amino groups and not satisfactory for reaction with the bifunctional conjugating reagents used to attach biomolecules.
- the reaction with diamine is performed under conditions that prevent crosslinking between nanoparticles. This is accomplished by using a large excess of diamine. In general the moles of diamine used will exceed the number of carboxyl groups present by a factor of at least 10. Diamines are cheap and can be used in very large excess. Unreacted diamine (MW ⁇ 2 kDa) can be separated from amino functionalized nanoparticle (MW>500 kDa) by ultrafiltration. Alternatives to ultrafiltration for the removal of unreacted diamine include gel permeation chromatography, dialysis, and precipitation and resolubilization of the nanoparticle.
- the amino functionalized nanoparticles of the invention have a characteristic general structure that includes a peptidyl bond and a primary amino group, see FIGS. 1 and 2C. This characteristic structure is not found with amino functionalized amino-CLIO nanoparticle.
- a peptide bond is not obtained when dextran coated magnetic iron oxides are activated by treatment with periodate, followed by reaction with a primary amine and treatment with a reducing agent. In this case a methyl amine linkage is obtained (FIG. 2B).
- the presence of primary amino groups on the magnetic nanoparticles can be readily ascertained by reaction with amine specific reagents such as TNBS or ninhydrin or SPDP with the in tact magnetic nanoparticle. Since the carboxyl groups are protected by the metal oxide, they can be most easily analyzed after digestion of the metal oxide core and isolation of the polymeric coating. Digestion of metal oxide core can be accomplished by treatment with acid and chelator. Typically a pH below 5, or between 2 and 5, is sufficient. Chelators like citrate or EDTA enhance the solubility of iron and are added an amount sufficient to bind all metal ions. After digestion, the metal is removed by passage over a cation exchange column or metal removing chelating column such as Chelex.
- the polymer is then analyzed by IR and shows characteristic peaks from carboxyl groups.
- Polymers with carboxyl groups have characteristic absorption frequencies from the carbonyl group (C ⁇ O) of the carboxyl (1780 to 1710 cm ⁇ 1, strong) and the hydroxyl group (3000 to 2500 cm ⁇ 1, broad, variable).
- the polymer obtained after digestion and removal of iron can also be characterized by size and compared with the polymer used in the nanoparticle synthesis.
- the polymer will be slightly larger than the starting polymer due to addition of amino groups.
- a second property of the amine functionalized polymers of the invention is presence of at least two nitrogen atoms for each primary amine due to characteristic general structure (H 2 N—X—NH—CO—), see also FIG. 2C.
- X can be any structure connecting the two primary amines of the diamine. Non limiting examples include hexamine diamine, ethylene diamine, spermidine or spermine, and amino acids like omithine or lysine, which are of interest because of their negatively charged carboxyl group.
- the total number of nitrogen groups attached to the purified polymer can be obtained by submitting the purified polymer to elemental analysis of nitrogen, i.e., determination of the content of all nitrogen atoms.
- the number of reactive primary amino groups can be determined by the TNBS method.
- a property of the amine functionalized polymers of the invention is the amount of total nitrogen will exceed the amount of nitrogen present as a primary amine. For example, when ethylene diamine (EDA) has been used, the total nitrogen content will be twice the nitrogen content obtained with methods determining the amount of primary amine.
- EDA ethylene diamine
- polycarboxylated polymers for the synthesis of coated nanoparticle.
- the polycarboxylated polymers can be obtained by a variety of routes and have a variety of compositions. They may be man made or naturally occurring and may be highly branched or linear.
- the polycarboxylated polymers have a molecular weight between about 5 and 200 kDa, more preferably between 5 and 50 kDa. Smaller polymers lack a sufficient number of carboxyl groups to both strongly bind to the iron oxide and have the numerous free carboxyl groups available for conversion to amino groups (FIG. 1). The polymers must contain more than about five moles of carboxyl group per mole of polymer. The number of carboxyl groups can be determined by titration. The polycarboxylated polymers should have a high water solubility over a wide range of pH's to be employed in the synthesis of water soluble polymer coated magnetic nanoparticles.
- unreacted polymer must be separated from polymer coated nanoparticle.
- the polymer maintain a homogenous size distribution, which can be determined by the usual methods of polymer chemistry including light scattering, gel permeation chromatography.
- MW>500 kDa coated nanoparticle
- Polymers larger than about 200 kDa can used but they are more difficult and more expensive to separate from the polymer coated nanoparticles as the larger molecular weight polymers and the polymer coated nanoparticles pass through the same membrane.
- a preferred method of synthesizing polycarboxylated polymers is the reaction of a water soluble polymer containing multiple amino or hydroxyl groups with an alkyl halogenated acid in aqueous strong base.
- This method has several advantages. First, the size and size distribution of the polymer obtained will be determined the size of the starting polymer. Hence by selecting a size homogeneous polymer, the size homogenity of the carboxylated polymer is achieved. The size of the polycarboxylated polymer will be slightly larger than the starting polymer due to the addition of carboxyl groups. For details see examples 1, 4 and 6, of Josephson et al WO97/21452.
- polymers with varying number of carboxyl groups on them can be synthesized by varying the amount of halogenated acid, to determine the optimum level of carboxylation required for the synthesis of polymer coated magnetic nanoparticle, see Groman WO 00/61191.
- An alternative method is the direct synthesis of polycarboxylic functional polymers, such as polymethacrylic acid based polymers.
- Naturally occurring hydroxylated polymers that can be used in the synthesis of polycarboxylated polymers include polysaccharides like dextran, starch or cellulose.
- Polyvinyl alcohol is a synthetic hydroxylated polymer that can replace naturally occurring polysaccharides. These hydroxyl group-bearing polymers are reacted with halogenated acids like bromoacetic acid, chloroacetic acid, bromohexanoic acid and chlorohexanoic acid in the present of strong base, typically 1-8 M NaOH.
- the polycarboxylated polymer is then purified by ultrafiltration or by precipitation.
- anhydrides like succinic anhydride can be used for carboxylation polyhydroxylated polymers, but these result in ester linkages which can undergo slow hydrolysis.
- Hydrolysis of an anhydride containing polymer is another method that can yield a suitable carboxylated polymer.
- Carboxyl group bearing polyamino acids can also be employed as polycarboxylated polymers., e.g. polyaspartate or polyglutamate.
- Carboxylated dendrimers are available commercially and are highly branched synthetic polymers and can be used in the synthesis of nanoparticles.
- Carboxy terminated nanoparticles can be synthesized by mixing the carboxyl terminated polymer with ferrous and ferric salts.
- Metals other than iron can be used in the synthesis of magnetic metal oxides.
- zinc, manganese or cobalt can partially or completely replace the ferrous ion during the synthesis of magnetic metal oxides.
- the mixture is enclosed in a jacked reactor for temperature control and stirred. It is covered to control access of oxygen.
- the mixture is then brought to controlled temperature between 4 and 20 C., and a base, such as ammonia, is added. Base is added in a highly controlled fashion, either by pumping or by drop wise addition. Sufficient base is added to bring the pH to higher than pH 8, which causes the formation of iron oxides.
- the resulting gel or colloid maybe heated, to induce formation of the highly magnetic iron oxide.
- the temperature of the mixture is heated to above 60 C. for more than 30 minutes. Finally, the colloid is allowed to cool and unreacted polymer removed from the polymer coated nanoparticle.
- the preferred technique for removal is ultrafiltration, using a membrane that has a cutoff that permits the carboxylated polymer to pass through, while the larger coated nanoparticle is retained.
- Alternatives to ultrafiltration are gel filtration and magnetic separation. Citrate maybe added as stabilizer but it must be removed by ultrafiltration before use of carbodiimide because of its carboxyl groups. Details methods for the synthesis of polycarboxylated polymer coated nanoparticles can be found in Groman and Manro
- the carboxyl groups of the carboxyl terminated nanoparticle are then activated by the use of a water soluble carbodiimide. Typically this is done in a non-amine containing buffer between pH 4.5 and 7. The activation with 0.1 M TEMED, pH 4.8 has been found to satisfactory. Activation is typically done at 20-40 C. EDA) is added in vast excess to prevent the formation of crosslinks between the carboxyl groups. Excess diamine can be separated from the aminated, polymer coated nanoparticle using ultrafiltration. The use of carbodiimide results in the formation of a peptide bond between the diamine linker and polymeric nanoparticle coating. The number of primary amines on the particle can be monitored by reaction with trinitrobenze. A variety of diamines can be used such as hexamine diamine, ethylene diamine, spermidine or spermine. Amino acids like omithine or lysine are diamines of interest because of their negatively charged carboxyl group.
- the aminofunctionalized nanoparticles can be used as attachment substrates to form a variety of nanoparticle conjugates for in vivo or in vitro applications.
- Example applications include cell sorting, in vitro assays and in vivo applications such as magnetic resonance imaging.
- a non limiting exemplary conjugate is a biomolecule nanoparticle conjugate.
- the amino terminated nanoparticle is then reacted with a bifunctional conjugation reagent designed to react with amino groups.
- Preferred conjugation reagents are NHS esters, which react with the amine group of the nanoparticle, and which have second moiety that can react with the sulfhydryl group of the biomolecule.
- crosslinking agents include, for example, SPDP, long chain-SPDP, SIA, MBS, SMCC, and others that are well known in the art and are available from Piece Chemical Company. Detailed procedures for their are available from the Piece Chemical web site, see http://www.piercenet.com/ and the attached pdf files downloaded from that site.
- the activated biomolecule is allowed to react with the activated nanoparticle. Separation of unreacted biomolecule from the biomolecule-nanoparticle conjugates can be accomplished by gel filtration, ultrafiltration, dialysis or magnetic separation methods.
- Examples of thiolated biomolecules that have been attached to SPDP activated crosslinked magnetic nanoparpticles include transferrin, (Hogemann, (2000) Bioconjug Chem 11, 941-6), tat peptides (Josephson, (1999) Bioconjug Chem 10, 186-91; Zhao (2002) Bioconjug Chem 13, 840-4), oligonucleotides (Josephson (2001) Agnew Chem Int Ed 40, 3204-3206; Perez, (2002) J Am Chem Soc 124, 2856-7), antibodies (Kang,. (2002) Bioconjug Chem 13, 122-7) and proteins (Perez, Nature Biotechnol 20, 816-20).
- transferrin Hogemann, (2000) Bioconjug Chem 11, 941-6
- tat peptides Josephson, (1999) Bioconjug Chem 10, 186-91; Zhao (2002) Bioconjug Chem 13, 840-4
- the magnetic nanoparticles of the invention have various uses with in vitro ligand binding assays.
- the nanoparticles can be used in magnetic detection based assays (see Simmonds U.S. Pat. Nos. 6,046,585 and 6,275,031, Rohr U.S. Pat. No. 5,445,970; Ebersole, U.S. Pat. No. 4,219,335, Chemla, et. al. (2000) Ultrasensitive magnetic biosensor for homogeneous immunoassay. Proc Natl Acad Sci USA 97, 14268-72.). They can also be used in magnetic resonance based ligand binding assays such as Josephson U.S. Pat. No. 5,164,297 and Perez et al Nature Biotechnol . 2002 August;20(8):816-20.
- Magnetic nanoparticles of the invention of the invention are also suitable for cell sorting applications. Magnetic nanoparticles were described by Molday U.S. Pat. No. 4,452,773 and commercially available (Miltenyi Biotech, Auburn Calif., and Molecular Probes, Eugene Oreg.).
- magnetic nanoparticles of the invention can be used as for targeted MR imaging applications.
- the biomolecule-nanoparticle conjugates are formulated and sterilized according to the published methods for sterilizing parenterally administered MRI contrast agents.
- sterilization can be achieved by filtering the colloid through a 220 nm filter (filter sterilization) or by heat sterilization (terminal sterilization).
- various excipients such as monosaccharides, polysaccharides, salts, can be added to stabilize the colloid during heat stress or storage. Excipients can also serve to bring the ionic strength and pH of the preparation into the physiological range. See Josephson U.S. Pat. No. 5,160,726, Groman U.S. Pat. No. 5,248,492.
- Carboxymethylated polymers are prepared by reaction of a halo acetic acid with a polymer in strong base, usually NaOH.
- the polymer should be of sufficient molecular weight to allow separation from unreacted haloacetic acid from the carboxymethylated polymer.
- the polymer is preferably between 5 kDa and 100 kDa. The separation can be accomplished by dialysis, ultrafiltration or precipitation. The polymer is then dried by lyophilization, vacuum drying or spray drying.
- the polymer should be of sufficient molecular weight to allow separation of dextran from dextran coated iron oxide. For example, when the nanoparticles have molecular weights of greater than 500 kDa, and the polymer is preferably less than 100 kDa, this separation can be accomplished by ultrafiltration.
- the colloid had a size of 54 nm by light scattering and an R2 of 60 mM-1 sec ⁇ 1.
- the procedure was repeated using 3 g CM-PVA to give a colloid with 65 nm and an R2 of 160 mM ⁇ 1 sec ⁇ 1.
- Nanoparticles were reacted with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP).
- SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
- To 1 mL of amino functionalized magnetic nanoparticle (10 mg Fe) was added 1 mL of 0.1 M phosphate buffer, pH 7.4, and 2 mL of 25 mM SPDP in DMSO (50 umoles SPDP). The mixture was allowed to stand for 60 min at room temperature. Low molecular impurities were removed by PD-10 columns (Sigma Chemical, St. Louis, Mo.) equilibrated with 0.01 MTris and 0.02 Mcitrate, pH 7.4 buffer. The number of amine groups can be obtained for the amount of 2PT released assayed by addition of dithiothreitol. (Zhao, (2002) Bioconjug Chem 13, 840-4).
Abstract
Amine functionalized magnetic nanoparticle compositions and processes for synthesizing the same are described. The process consists of obtaining a carboxylated polymer in substantially pure form, which is used to prepare a substantially size homogeneous, polymer coated carboxyl, functionalized magnetic nanoparticle. The carboxyl groups are converted to reactive primary amino groups by the use of a water-soluble carbodiimide followed by reaction of a large excess of a diamine. The amine-terminated nanoparticles are then reacted with bifunctional crosslinking agents and with various biomolecules to make nanoparticles for in vitro assays, cell sorting applications and target specific MR contrast agents.
Description
- This Application claims priority under 35 USC 119(e) to provisional patent application U.S. No. 60/345,233 filed Jan. 2, 2002.
- The present invention relates to novel superparamagnetic nanoparticle compositions, synthesis and uses thereof.
- All patents, patent applications and references cited in this specification are incorporated herein by reference.
- Carboxyl bearing polymers have found a wide usage in food, drugs, and industrial applications. A few well known examples include the carboxymethyl (‘CM’) polysaccharides CM-cellulose, CM-dextran, and CM-arabinogalactan (U.S. Pat. No. 5,981,507). The CM polysaccharides are produced from a reaction of the polysaccharide with haloacetic acids in base.
- Carboxyl bearing polymers have been used in the synthesis of magnetic nanoparticles. Carboxylated dextrans of two major types have been used in the synthesis of superparamagnetic iron oxide nanoparticles. Carboxydextrans have a single terminal carboxyl group on each dextran molecule obtained by treatment with base (Hasegawa U.S. Pat. No. 4,101,435; Hasegawa U.S. Pat. No. 5,424,419,
column 2, line 17). Carboxymethylated dextrans have numerous carboxymethyl groups attached per mole of dextran by reaction of alkyl halogenated acids in base (Maruno U.S. Pat. No. 5,204,457; Groman WO 00/61191). - Magnetic nanoparaticles used for the attachment of biomolecules have been described by Molday (U.S. Pat. No. 4,452,773). A dextran coated magnetic nanoparticle is formed and then treated with periodate to produce aldehyde groups. The aldehydes react with amino groups on a biological molecule, to form a Schiff base. The Schiff base maybe stabilized by treatment of with a reducing agent like sodium borohydride. After treatment with a reducing agent a methylene amino linker connects the biomolecule to the nanoparticle. As shown in FIG. 2B, there are no peptidyl bonds in such linkages. A drawback of this method is the difficulty controlling the number and position of amino groups on the biomolecule that are available to react with the reactive aldehyde groups on the nanoparticle.
- Other methods of attaching biomolecules to nanoparticles also use the reactivity of the aldehyde group. Rembaum and coworkers have utilized this approach, synthesizing nanoparticles with glutaraldehyde (U.S. Pat. Nos. 4,438,239; 4,369,226).
- The development of amine functionalized crosslinked iron oxide nanoparticle (“amino-CLIO”, FIG. 2) by one of the inventors has proven to be an excellent method of synthesizing magnetic particle-biomolecule conjugates. Amino-CLIO is prepared by first synthesizing a dextran coated magnetic nanoparticle, followed by crosslinking the dextran with epichlorohydrin. Finally the amine groups are incorporated by reacting the dextran with ammonia (see Josephson et al, (1999) Bioconjug Chem 10, 186-91; Josephson et. al (2001) Angwandte Chemie 40, 3204-3206;).
- Amino-CLIO is an excellent label for the attachment of biomolecules, and for the synthesis of magnetic nanoparticle-biomolecule conjugates, for two reasons. First it provides an amine group for reaction with many bifunctional conjugation reagents that consist of N-hydroxysuccinimide esters that react first with an amine group and have a second group that reacts with sulfhydryl groups on a biomolecule. Examples of these bifunctional conjugating reagents are SPDP, SIA, SMCC and MBS. These reagents are available commercially (Pierce Chemical or Molecular Biosciences). Examples of biomolecules that have been attached to amino-CLIO include peptides (Josephson et al, (1999) Bioconjug Chem 10, 186-91), oligonucleotides (Josephson et. al (2001) Angwandte Chemie 40, 3204-3206;) and proteins (Hogemann et al. (2000). Bioconjug Chem 11, 941-6). Second, amino-CLIO is highly stable due to the fact that the crosslinking forms a shell of dextran around a core of iron oxide. This allows storage of either amino-CLIO or bioconjugates based on amino-CLIO under a wide range of conditions (temperature, pH, ionic strength). By covalently joining polymeric molecules of the coating, crosslinking is associated with a pronounced increase in the molecular weight of the polymeric coating.
- This amino-CLIO based chemistry has one major drawback, however, which arises precisely because of the extraordinary stability achieved by using a crosslinked-stablilized dextran on the nanoparticle surface. For human parenteral applications, such as for a magnetic label for targeted MR contrast agents, the degradation or elimination of the agent, including the coating, is required. However, when the iron oxide of an amino-CLIO based MR contrast is dissolved or biodegraded, the crosslinked dextran remains as a non-degradable sphere of polysaccharide. Similarly, non-degradability occurs with micron-sized magnetic microspheres where iron oxide is entrapped in a non-biodegradable polymeric shell (see U.S. Pat. Nos. 4,654,267; 5,512,439).
- CM-polymers can also function as starting materials for the synthesis of drugs conjugates or for the attachment of various biological molecules. As drug conjugates, CM-arabinogalactan, CM-dextran and polyvinyl alcohol were used as carriers for nucleotide analogues (U.S. Pat. No. 5,981,507). The carboxyl groups were converted to primary amino groups by reaction with diamines. Biological molecules like araAMP were then attached to the primary amine of the aminated arabinogalactan, see Josephson, et al. (1996)Antivir Ther 1, 147-56 and U.S. Pat. No. 5,478,576.
- In these examples, the CM-polymers, such as CM-arabinogalactan, exist as macromolecules in solution, which allows conditions to be employed that insure the nearly quantitative conversion of carboxyl groups to amino groups. The absence of protected carboxyl groups allows essentially all carboxyl groups to be chemically reactive.
- There is a need for a improved magnetic nanoparticles to which biomolecules can be attached for use in cell sorting applications, in vitro assays, and which can be used as an intravenously administerable, MR contrast agents. The ideal nanoparticle must have a surface chemistry amenable to the efficient attachment of biomolecules with retention of their biological activity. It must be highly stable in vitro, both before and after the attachment of biomolecules. Yet it must be labile or degradable in vivo, with the utilization or elimination of all of its components.
- The present invention relates to aminofunctionalzied nanoparticles. In one embodiment, the nanoparticles have a magnetic core having one or more magnetic metal oxide crystals, and a noncrosslinked polymer coating associated with the core. The polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups. A portion of the carboxyl groups are associated with the crystals. In one embodiment, a portion of the amino groups are associated with polymer through a peptidyl linkage of the formula:
- —O—(CH2)m—CONH—[X]
- wherein X is —(CH2)nNH2, —(CH2)oCH NHCOO—, —(CH2)3NH(CH2)4NH2 or —(CH2)3NH(CH2)4NH(CH2)3 NH2—
- wherein m=1, 2, or 3; n=2, 3, 6, and o=3 or 4.
- In one embodiment, the magnetic core has one or more superparamagnetic iron oxide crystals. The superparamagnetic core has a diameter between about 1 nm and about 25 nm, preferably between about 3 nm and about 10 nm, and more preferably about 5 nm.
- The nanoparticle (core and polymer) has diameter between about 15 nm and 100 nm, preferably between about 20 nm and about 100 nm.
- The polymer coating may be made from natural polymers, or synthetic polymers, or derivatives or each. Nonlimiting examples include polyvinyl alcohol and carboxymethyldextran In one aspect of the invention, the nanoparticle can be conjugated to a biomolecule.
- In another aspect of the invention, there is provided a nanoparticle biomolecule conjugate. The nanoparticle portion includes a magnetic core having one or more magnetic metal oxide crystals, a noncrosslinked polymer coating associated with the core. As in the previous emboidiment, the the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups. A portion of the carboxyl groups are associated with the crystals, In one embodiment, the amino groups are associated with polymer through a peptidyl linkage of the formula:
- —O—(CH2)m—CONH—[X]
- wherein X is —(CH2)nNH2, —(CH2)oCH NHCOO—, —(CH2)3NH(CH2)4NH2 or —(CH2)3NH(CH2)4NH(CH2)3NH2—
- wherein m=1, 2, or 3; n=2, 3, 6, and o=3 or 4; and
- whereby a a biomolecule is linked to the nanoparticle through the amino group.
- In another aspect of the invention, there is provided a process for synthesizing an amine functionalized magnetic metal oxide nanoparticle via the steps of (i) obtaining a polymer having a plurality of carboxyl groups attached thereto, (ii) contacting the polymer with magnetic metal oxide to produce a coated magnetic metal oxide wherein a portion of said carboxyl groups are associated with the metal oxide; and (iii) reacting the coated magnetic metal oxide of step (ii) with a diamine. In one embodiement the diamine is ethylene diamine; in another embodiment the diamine is hexane diamine.
- In another aspect of the invention, the contacting step in the synthesis further includes the steps of (a) providing a solution of soluble iron salts; (b) converting the iron salts into iron oxide crystals; and (c) removing unassociated polymer. In yet another aspect of the invention, the converting process includes the further steps of (a) heating the iron salts to a temperature between about 4° C. and about 20° C.; and adding an amount of base to raise the pH to about 8 or higher to form iron oxides. In another aspect, the process includes the step of heating the iron oxides to a temperature about 60° C. or more for at least 30 minutes.
- Another aspect of the invention provides a pharmaceutical composition of the nanoparticle biomolecule conjugates and a pharmaceutically acceptable carrier. This composition is particularly useful in targeted MR imaging applications.
- In all figures, the large sphere represents the core magnetic material.
- FIG. 1 shows a reaction scheme for synthesis of amino functionalized magnetic nanoparticles. First, a
polymer 1 having multiple carboxyl groups is obtained. Next, the polymer is used to synthesize a coated nanoparticle. The core magnetic material is shown as adark sphere 2. Carboxyl groups face (i) both the magnetic core which are blocked (arrow 3 b) and (ii) the solvent (arrow 3 a) and are available for further reaction. Third, the free carboxyl groups are reacted, here with carbodiimide, to produce the amine functionalizednanoparticle 4. - FIGS.2A-C are comparisons of the prior art nanoparticles (FIGS. 2A and 2B) with the nanoparticles of the invention (2C).
- In FIG. 2A, the prior art nanoparticles use crosslinked dextran and ammonia. This produces a functionalized particle in which every nitrogen is a primary amine. The polymer is associated with the magnetic core (large sphere) via hydroxyl groups.
- In FIG. 2B, the prior art nanoparticles use non-crosslinked dextran which has been reacted with periodate to form aldehydes, followed with EDA and a reducing agent. There are two nitrogen atoms for every primary amine: a terminal amino group (1) linked to the polymer through methyl amine groups (the dashed box, showing second amine 2). There are no peptidyl linkages. The polymer is associated with the magnetic core (large sphere) via hydroxyl groups.
- FIG. 2C shows the nanoparticles of the present invention. The polymer is noncrosslinked, and the amino group is linked to the polymer via a peptide bond. There are two nitrogen atoms for each primary amine:
terminal amine 1 and atpeptidyl linkage 2. The noncrosslinked polymer is associated with the magnetic core (large sphere) via carboxyl groups. - The present invention meets the aforementioned requirements by providing novel compositions of amino functionalized nanoparticles, and their methods of synthesis. These novel amino functionalized nanoparticles can serve further as magnetic nanoparticles for the development biomolecule-magnetic nanoparticle conjugates useful in a variety of in vitro, and in vivo applications.
- Definitions
- A nanoparticle as described and claimed herein is a material with a “core” of magnetic material associated with a polyfunctional noncrosslinked polymer. The polymer coating displays a plurality of carboxyl groups and reactive primary amino groups; a portion of the carboxyl groups are associated with the magnetic core; the reactive primary amino groups are available for subsequent covalent reactions, e.g., for the attachment of biomolecules. The nanoparticles have an overall size less than about 100 nm, before conjugation to biomolecules. The overall size of the nanoparticles is about 15 to 100 nm, preferably about 20 to 100 nm, more preferably about 40 to 60 nm; about 50 nm is the most preferred. The polymeric coating can be about 5 to 20 nm thick or more. Size can be determined by laser light scattering by atomic force microscopy or other suitable techniques.
- The nanoparticle core can be monodisperse (a single crystal of a magnetic material, e.g., metal oxide, such as superparamagnetic iron oxide, per particle) or polydisperse (a plurality of crystals, e.g., 2, 3, or 4, per particle). The metal oxides are crystals of about 1-25 nm, preferably about 3-10 nm, and most preferably about 5 nm in diameter. The magnetic metal oxide can also comprise cobalt, magnesium, zinc, or mixtures of these metals with iron. The term “magnetic” as used in this specification and the accompanying claims means materials of high positive magnetic susceptibility.
- In a preferred embodiment, a superparamagnetic form of iron oxide is used. Superparamagnetic iron oxide is one of the highly magnetic forms (magnetite, non-stoichiometric magnetite, gamma-ferric oxide) that has a magnetic moment of greater than about 30 EMU/gm Fe at 0.5 Tesla and about 300 K. When magnetic moment is measured over a range of field strengths, it shows magnetic saturation at high fields and lacks magnetic remanence when the field is removed.
- The “polymer coating” is a natural or synthetic polymer associated with the magnetic core that functions to keep the metal oxides dispersed from each other. In one embodiment the polymer “coating” is not a continuous film around the magnetic metal oxide, but is a “mesh” or “cloud” of extended polymer chains attached to and surrounding the metal oxide. The polymer coating may be a natural polymer, a synthetic polymer. The polymer maybe linear, or moderately or highly branched. In one embodiment, the polymer coating can be carboxy dendrimers, commercially available from Sigma-Aldrich, which are highly branched polycarboxyl polymers. Other embodiments of the polymer coating are described in detail below.
- A natural polymer is obtained when a pure polymer, such as a polysaccharide, is synthesized by a microorganism, plant or animal and extracted in substantially pure form. Non limiting examples of natural polymers include polysaccharides, such as dextran. A synthetic polymer is obtained from nonbiological syntheses, by using standard polymer chemistry techniques known to those in the art to react monomers into polymers. The polymers may be homopolymers, i.e, synthesized from a single type of monomer, or co-polymers, i.e., synthesized from two or more types of monomers. Non-limiting examples of synthetic polymers include polymethylmethacrylate polymers and polyvinyl alcohol polymers.
- A crosslinked polymer is one in which functional groups on a polymer chain and/or branches has reacted with functional groups on another polymer to form polymer networks. Crosslinked polymers are characterized herein as being heat stable and resistant to breakdown in biological systems. A crosslinked polymer has a molecular weight significantly higher than the original starting polymer.
- A non-crosslinked polymer is described and claimed herein as a polymer in which few or no individual polymer chains have reacted with the functional groups of another polymer chain to form the interconnected polymer networks. A non-crosslinked polymer that has been functionalized is reasonably size homogeneous as compared to the starting polymer, i.e., the polymer before and after incorporation of amine and carboxyl functional groups have similar molecular weights and molecular weight distributions. A small increase in molecular weight of the polymer is seen generally as a result of the incorporation of functional groups onto the polymer and the few crosslinks that may occur on a statistical basis.
- A polycarboxyl (or carboxyl) polymer is a polymer with more than one carboxyl group per polymer.
- A polyfunctionalpolymer is one with different functional groups, such as amino and carboxyl groups attached to a polymer.
- Description
- We have surprisingly discovered that amino functionalized nanparticles can be synthesized using non crosslinked, carboxylated polymers, and that these polymers permit the addition of reactive primary amine groups to the polymer. These reactive primary amines are attached to the polymer via peptidyl linkages.
- When the noncrosslinked carboxylated polymers are used in the synthesis of the nanoparticles, the resulting polymer coated nanoparticle has two classes of carboxyl groups with very different chemical reactivities. Some carboxyl groups are shielded from further chemical reaction by forming a strong bond between the polymer and the surface of the iron oxide. Some surface carboxyl groups, facing the bulk solvent, can be activated with carbodiimide and converted to reactive primary amino groups (FIG. 1). These reactive primary amines can be reacted with bifunctional conjugating agents and then with biomolecules to form targeted MR contrast agents, or probes for used in biosensors.
- As shown in FIG. 1, the process for synthesizing magnetic nanoparticies involves three general steps: (i) obtaining a polycarboxylated polymer; (ii) synthesizing a polycarboxylated coated magnetic nanoparticle; and (iii) converting the surface carboxyl groups to reactive primary amine groups while the remaining carboxyl groups bind the polymer to the nanoparticle (FIG. 1).
- As a result of this procedure, the magnetic nanoparticles of the invention have polyfunctional polymeric coating, i.e. one that contains both amino and carboxyl groups. Since the carboxylated polymer used to synthesize the magnetic nanoparticle in step (ii) possesses only a single class of carboxyl groups, it is highly surprising that the resulting polymer coated magnetic nanoparticle consists of two distinct types of carboxyl groups. One type is bound to the surface of the iron oxide (blocked from further chemical reaction). A second type is exposed to the bulk solvent and available for conversion to reactive primary amino groups, see FIG. 1. Moreover, the chemistry used to incorporate the functional groups results in a polymer coating that is noncrosslinked (i.e, uncrosslinked or minimnally crosslinked).
- The presence of both reactive primary amino and carboxyl groups on the polymeric coating of the magnetic nanoparticles is one of the distinctive features of the invention. Polymers containing both reactive primary amino groups and carboxyl groups are difficult to develop because of the propensity for self-reaction. In solution at neutral pH, the positively charged carboxyl group and negatively charged amino group form non-covalent electrostatic bonds. When covalent modification of amino and carboxyl group containing polymers is attempted, activation of the carboxyl groups with a carbodiimide results in the formation of peptidyl bonds by reaction amino groups on the same molecule. This results in intrachain crosslinking when the reactive amino groups are on the same polymer, or interchain crosslinking when the amino group is on a second polymer molecule. Such interchain cross-linking can be induced in proteins, which present a mixture of amino and carboxyl groups on the surface, by activating agents like carbodiimide and is used to make aggregates of soluble proteins. For this reason the synthesis of polymers such as peptides containing amino and carboxyl groups requires use of protecting groups followed by deprotection. The synthesis used here eliminates the protection-deprotection reaction steps.
- Another feature of the amine functionalized nanoparticles of the invention is that they can be readily degraded to yield their metal salts and polymer coating. In one embodiment, the degradation yields iron salts and the polyfunctional polymeric coating. In vivo, this results in the utilization of iron oxide, by incorporation of iron into red blood cells, and by the excretion and/or degradation of the polycarboxylated polymer. In vitro, the conditions of biodegradation can be simulated by exposing nanoparticles to mildly acidic pH (3-6) in the presence of a metal chelator, e.g. citrate or EDTA. This yields ferric ion chelates and soluble polyfunctional polymers. The molecular weight of the polyfunctional polymers, bearing amino and carboxyl groups, will be slightly larger than the polycarboxylated polymers used to synthesize the nanoparticles due the addition of reactive primary amino groups.
- The amine functionalized nanoparticles of the invention are synthesized by activation of free carboxyl groups of the nanoparticle with a water soluble carbodiimide, followed by reaction with a large excess of a diamine. The nature of the diamine provides a linker arm of varying lengths and chemistries for the attachment of biomolecules. Nonlimiting examples of diamines include ethylenediamine (EDA), propyldiamine, spermidine, spermine, hexanediamine, and diamine amino acids, such as lysine or omithine.
- Unlike the synthesis for other amine functionalized particles, ammonia is not used to make the amine functionalized nanoparticles of the invention. For example, in the synthesis of amino-CLIO, dextran coated magnetic nanoparticles are reacted with epichlorohydrin, followed by reaction with ammonia. This reaction produces a dextran crosslinked, amine functionalized nanoparticle bearing primary amino groups (H2N—CH2—CHOH—CH2—O-Polymer), as shown in FIG. 2A. If the carbodiimide activated carboxylated nanoparticles of this invention were reacted with ammonia, an amide would be obtained (H2N—CO—CH2—O-Polymer). The nitrogen atoms of amides are far less reactive than primary amino groups and not satisfactory for reaction with the bifunctional conjugating reagents used to attach biomolecules.
- The reaction with diamine is performed under conditions that prevent crosslinking between nanoparticles. This is accomplished by using a large excess of diamine. In general the moles of diamine used will exceed the number of carboxyl groups present by a factor of at least 10. Diamines are cheap and can be used in very large excess. Unreacted diamine (MW<2 kDa) can be separated from amino functionalized nanoparticle (MW>500 kDa) by ultrafiltration. Alternatives to ultrafiltration for the removal of unreacted diamine include gel permeation chromatography, dialysis, and precipitation and resolubilization of the nanoparticle.
- When the carbodiimide activated carboxylated nanoparticles of the invention are reacted with a large excess of diamine, one of the nitrogen atoms reacts with the carboxyl group to provide a peptide bond, while a second exists as a primary amine suitable for further chemistry. Hence the amino functionalized nanoparticles of the invention have a characteristic general structure that includes a peptidyl bond and a primary amino group, see FIGS. 1 and 2C. This characteristic structure is not found with amino functionalized amino-CLIO nanoparticle. Similarly, a peptide bond is not obtained when dextran coated magnetic iron oxides are activated by treatment with periodate, followed by reaction with a primary amine and treatment with a reducing agent. In this case a methyl amine linkage is obtained (FIG. 2B).
- The presence of primary amino groups on the magnetic nanoparticles can be readily ascertained by reaction with amine specific reagents such as TNBS or ninhydrin or SPDP with the in tact magnetic nanoparticle. Since the carboxyl groups are protected by the metal oxide, they can be most easily analyzed after digestion of the metal oxide core and isolation of the polymeric coating. Digestion of metal oxide core can be accomplished by treatment with acid and chelator. Typically a pH below 5, or between 2 and 5, is sufficient. Chelators like citrate or EDTA enhance the solubility of iron and are added an amount sufficient to bind all metal ions. After digestion, the metal is removed by passage over a cation exchange column or metal removing chelating column such as Chelex. The polymer is then analyzed by IR and shows characteristic peaks from carboxyl groups. Polymers with carboxyl groups have characteristic absorption frequencies from the carbonyl group (C═O) of the carboxyl (1780 to 1710 cm−1, strong) and the hydroxyl group (3000 to 2500 cm−1, broad, variable).
- The polymer obtained after digestion and removal of iron can also be characterized by size and compared with the polymer used in the nanoparticle synthesis. The polymer will be slightly larger than the starting polymer due to addition of amino groups.
- A second property of the amine functionalized polymers of the invention is presence of at least two nitrogen atoms for each primary amine due to characteristic general structure (H2N—X—NH—CO—), see also FIG. 2C. X can be any structure connecting the two primary amines of the diamine. Non limiting examples include hexamine diamine, ethylene diamine, spermidine or spermine, and amino acids like omithine or lysine, which are of interest because of their negatively charged carboxyl group. The total number of nitrogen groups attached to the purified polymer can be obtained by submitting the purified polymer to elemental analysis of nitrogen, i.e., determination of the content of all nitrogen atoms. The number of reactive primary amino groups can be determined by the TNBS method. A property of the amine functionalized polymers of the invention is the amount of total nitrogen will exceed the amount of nitrogen present as a primary amine. For example, when ethylene diamine (EDA) has been used, the total nitrogen content will be twice the nitrogen content obtained with methods determining the amount of primary amine.
- Properties and sources of polycarboxylated polymers for the synthesis of coated nanoparticle. The polycarboxylated polymers can be obtained by a variety of routes and have a variety of compositions. They may be man made or naturally occurring and may be highly branched or linear.
- The polycarboxylated polymers have a molecular weight between about 5 and 200 kDa, more preferably between 5 and 50 kDa. Smaller polymers lack a sufficient number of carboxyl groups to both strongly bind to the iron oxide and have the numerous free carboxyl groups available for conversion to amino groups (FIG. 1). The polymers must contain more than about five moles of carboxyl group per mole of polymer. The number of carboxyl groups can be determined by titration. The polycarboxylated polymers should have a high water solubility over a wide range of pH's to be employed in the synthesis of water soluble polymer coated magnetic nanoparticles.
- To be used in the synthesis of polymer coated magnetic nanoparticles, unreacted polymer must be separated from polymer coated nanoparticle. To do this easily and efficiently, it is preferred that the polymer maintain a homogenous size distribution, which can be determined by the usual methods of polymer chemistry including light scattering, gel permeation chromatography. For example, unreacted carboxymethylated dextran (MW=20 kDa) can be readily separated from the coated nanoparticle (MW>500 kDa) by ultrafiltration using a membrane with a cutoff of 100 kDa (Groman WO 00/61191). Polymers larger than about 200 kDa can used but they are more difficult and more expensive to separate from the polymer coated nanoparticles as the larger molecular weight polymers and the polymer coated nanoparticles pass through the same membrane.
- A preferred method of synthesizing polycarboxylated polymers is the reaction of a water soluble polymer containing multiple amino or hydroxyl groups with an alkyl halogenated acid in aqueous strong base. This method has several advantages. First, the size and size distribution of the polymer obtained will be determined the size of the starting polymer. Hence by selecting a size homogeneous polymer, the size homogenity of the carboxylated polymer is achieved. The size of the polycarboxylated polymer will be slightly larger than the starting polymer due to the addition of carboxyl groups. For details see examples 1, 4 and 6, of Josephson et al WO97/21452. Second, polymers with varying number of carboxyl groups on them can be synthesized by varying the amount of halogenated acid, to determine the optimum level of carboxylation required for the synthesis of polymer coated magnetic nanoparticle, see Groman WO 00/61191. An alternative method is the direct synthesis of polycarboxylic functional polymers, such as polymethacrylic acid based polymers.
- Naturally occurring hydroxylated polymers that can be used in the synthesis of polycarboxylated polymers include polysaccharides like dextran, starch or cellulose. Polyvinyl alcohol is a synthetic hydroxylated polymer that can replace naturally occurring polysaccharides. These hydroxyl group-bearing polymers are reacted with halogenated acids like bromoacetic acid, chloroacetic acid, bromohexanoic acid and chlorohexanoic acid in the present of strong base, typically 1-8 M NaOH. The polycarboxylated polymer is then purified by ultrafiltration or by precipitation. Alternatively anhydrides like succinic anhydride can be used for carboxylation polyhydroxylated polymers, but these result in ester linkages which can undergo slow hydrolysis.
- Reaction of positively charged polymers like polylysine or poly vinyl amine with an anhydride (succininc anhydride, maleic anhydride, DTPA anhydride) provide another method of synthesizing carboxylated polymers.
- Hydrolysis of an anhydride containing polymer, such as polytheyelene-alt-maleic anhydride (Sigma) is another method that can yield a suitable carboxylated polymer.
- Carboxyl group bearing polyamino acids can also be employed as polycarboxylated polymers., e.g. polyaspartate or polyglutamate. Carboxylated dendrimers are available commercially and are highly branched synthetic polymers and can be used in the synthesis of nanoparticles.
- Synthesis of carboxyl terminated, polymer coated nanoparticles.
- Carboxy terminated nanoparticles can be synthesized by mixing the carboxyl terminated polymer with ferrous and ferric salts. Metals other than iron can be used in the synthesis of magnetic metal oxides. For example, zinc, manganese or cobalt can partially or completely replace the ferrous ion during the synthesis of magnetic metal oxides.
- The mixture is enclosed in a jacked reactor for temperature control and stirred. It is covered to control access of oxygen. The mixture is then brought to controlled temperature between 4 and 20 C., and a base, such as ammonia, is added. Base is added in a highly controlled fashion, either by pumping or by drop wise addition. Sufficient base is added to bring the pH to higher than pH 8, which causes the formation of iron oxides. The resulting gel or colloid maybe heated, to induce formation of the highly magnetic iron oxide. The temperature of the mixture is heated to above 60 C. for more than 30 minutes. Finally, the colloid is allowed to cool and unreacted polymer removed from the polymer coated nanoparticle. The preferred technique for removal is ultrafiltration, using a membrane that has a cutoff that permits the carboxylated polymer to pass through, while the larger coated nanoparticle is retained. Alternatives to ultrafiltration are gel filtration and magnetic separation. Citrate maybe added as stabilizer but it must be removed by ultrafiltration before use of carbodiimide because of its carboxyl groups. Details methods for the synthesis of polycarboxylated polymer coated nanoparticles can be found in Groman and Manro
- Synthesis of amine terminated, polymer coated nanoparticles.
- The carboxyl groups of the carboxyl terminated nanoparticle are then activated by the use of a water soluble carbodiimide. Typically this is done in a non-amine containing buffer between pH 4.5 and 7. The activation with 0.1 M TEMED, pH 4.8 has been found to satisfactory. Activation is typically done at 20-40 C. EDA) is added in vast excess to prevent the formation of crosslinks between the carboxyl groups. Excess diamine can be separated from the aminated, polymer coated nanoparticle using ultrafiltration. The use of carbodiimide results in the formation of a peptide bond between the diamine linker and polymeric nanoparticle coating. The number of primary amines on the particle can be monitored by reaction with trinitrobenze. A variety of diamines can be used such as hexamine diamine, ethylene diamine, spermidine or spermine. Amino acids like omithine or lysine are diamines of interest because of their negatively charged carboxyl group.
- The aminofunctionalized nanoparticles can be used as attachment substrates to form a variety of nanoparticle conjugates for in vivo or in vitro applications. Example applications include cell sorting, in vitro assays and in vivo applications such as magnetic resonance imaging. A non limiting exemplary conjugate is a biomolecule nanoparticle conjugate.
- The amino terminated nanoparticle is then reacted with a bifunctional conjugation reagent designed to react with amino groups. Preferred conjugation reagents are NHS esters, which react with the amine group of the nanoparticle, and which have second moiety that can react with the sulfhydryl group of the biomolecule. Such crosslinking agents include, for example, SPDP, long chain-SPDP, SIA, MBS, SMCC, and others that are well known in the art and are available from Piece Chemical Company. Detailed procedures for their are available from the Piece Chemical web site, see http://www.piercenet.com/ and the attached pdf files downloaded from that site.
- The activated biomolecule, preferrably with a single sulfhydryl group distal from the site of bioactivity, is allowed to react with the activated nanoparticle. Separation of unreacted biomolecule from the biomolecule-nanoparticle conjugates can be accomplished by gel filtration, ultrafiltration, dialysis or magnetic separation methods. Examples of thiolated biomolecules that have been attached to SPDP activated crosslinked magnetic nanoparpticles include transferrin, (Hogemann, (2000)Bioconjug Chem 11, 941-6), tat peptides (Josephson, (1999) Bioconjug Chem 10, 186-91; Zhao (2002) Bioconjug Chem 13, 840-4), oligonucleotides (Josephson (2001) Agnew Chem Int Ed 40, 3204-3206; Perez, (2002) J Am Chem Soc 124, 2856-7), antibodies (Kang,. (2002) Bioconjug Chem 13, 122-7) and proteins (Perez, Nature Biotechnol 20, 816-20). For peptides (1-2 kDa), 5-25 peptides can be attached per 2000 Fe atoms. For proteins, such as transferrin or antibodies (50-200 kDa) 1-4 biomolecules can be attached per 2000 Fe atoms.
- Uses of the biomolecule-nanoparticle conjugates
- The magnetic nanoparticles of the invention have various uses with in vitro ligand binding assays. The nanoparticles can be used in magnetic detection based assays (see Simmonds U.S. Pat. Nos. 6,046,585 and 6,275,031, Rohr U.S. Pat. No. 5,445,970; Ebersole, U.S. Pat. No. 4,219,335, Chemla, et. al. (2000) Ultrasensitive magnetic biosensor for homogeneous immunoassay.Proc Natl Acad Sci USA 97, 14268-72.). They can also be used in magnetic resonance based ligand binding assays such as Josephson U.S. Pat. No. 5,164,297 and Perez et al Nature Biotechnol. 2002 August;20(8):816-20.
- The magnetic nanoparticles of the invention of the invention are also suitable for cell sorting applications. Magnetic nanoparticles were described by Molday U.S. Pat. No. 4,452,773 and commercially available (Miltenyi Biotech, Auburn Calif., and Molecular Probes, Eugene Oreg.).
- Finally the magnetic nanoparticles of the invention can be used as for targeted MR imaging applications.
- For in vivo uses, the biomolecule-nanoparticle conjugates are formulated and sterilized according to the published methods for sterilizing parenterally administered MRI contrast agents. For parenteral applications, sterilization can be achieved by filtering the colloid through a 220 nm filter (filter sterilization) or by heat sterilization (terminal sterilization). Depending on the method of sterilization various excipients, such as monosaccharides, polysaccharides, salts, can be added to stabilize the colloid during heat stress or storage. Excipients can also serve to bring the ionic strength and pH of the preparation into the physiological range. See Josephson U.S. Pat. No. 5,160,726, Groman U.S. Pat. No. 5,248,492.
- Synthesis of a carboxymethylated polyhydroxylated polymer
- Carboxymethylated polymers are prepared by reaction of a halo acetic acid with a polymer in strong base, usually NaOH. The polymer should be of sufficient molecular weight to allow separation from unreacted haloacetic acid from the carboxymethylated polymer. The polymer is preferably between 5 kDa and 100 kDa. The separation can be accomplished by dialysis, ultrafiltration or precipitation. The polymer is then dried by lyophilization, vacuum drying or spray drying. The polymer should be of sufficient molecular weight to allow separation of dextran from dextran coated iron oxide. For example, when the nanoparticles have molecular weights of greater than 500 kDa, and the polymer is preferably less than 100 kDa, this separation can be accomplished by ultrafiltration.
- (Poly)vinyl alcohol (100 g, MW=15 kDa) was dissolved in 1000 ml of hot water. After reaching room temperature, 600 ml of 8M NaOH solution was added to it with stirring and again equilibrates to room temperature. 100 g of bromo-acetic acid was then added and mixture stirred for two hours. The polymer was neutralized with 6M HCL It was then dried under vacuum overnight at room temperature. It is denoted CM-PVA.
- Synthesis of carboxymethylated polymer coated nanoparticle
- One hundred milliliters of a solution of 12 mmoles of ferric chloride (hexahydrate) and 6 grams of of CM-PVA. was prepared. The solution was filtered and cooled to 2-4 C. To the mixture was added 6 mmoles of ferrous chloride (tetrahydrate) dissolved in 5 mL of water. While being stirred rapidly, 4.5 mLs of 28-30% ammonium hydroxide (2-4 C.) was added dropwise. The mixture was then heated to between 70 and 90 C. and maintained at the higher temperature for 2 hours. Unreacted CM-PVA was removed by ultrafiltration using a 100 kDa cutoff membrane. The colloid had a size of 54 nm by light scattering and an R2 of 60 mM-1 sec−1. The procedure was repeated using 3 g CM-PVA to give a colloid with 65 nm and an R2 of 160 mM−1 sec−1.
- Conversion of carboxyl groups on the magnetic nanoparticle to amino groups
- To 10 mLs of 10 mg Fe/mL of the carboxylated polymer coated nanoparticle in 0.1 M TEMED buffer, pH 4.8, was added 0.2 g of 1-ethyl-3-(dimethylaminopropyl) carbodiimide hydrochloride at room temperature. After 15 mintues, 0.5
mL - Reaction of amino-functionalized magnetic nanoparticles with a biomolecule
- Nanoparticles were reacted with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP). To 1 mL of amino functionalized magnetic nanoparticle (10 mg Fe) was added 1 mL of 0.1 M phosphate buffer, pH 7.4, and 2 mL of 25 mM SPDP in DMSO (50 umoles SPDP). The mixture was allowed to stand for 60 min at room temperature. Low molecular impurities were removed by PD-10 columns (Sigma Chemical, St. Louis, Mo.) equilibrated with 0.01 MTris and 0.02 Mcitrate, pH 7.4 buffer. The number of amine groups can be obtained for the amount of 2PT released assayed by addition of dithiothreitol. (Zhao, (2002) Bioconjug Chem 13, 840-4).
- It will be apparent to those skilled in the art that other changes and modifications may be made in the above-described compounds, compositions, and methods for making and using the same, without departing from the scope of the invention herein, and it is intended that all matter contained in the above description shall be interpreted in an illustrative and not in a limiting sense.
Claims (21)
1. A nanoparticle comprising:
(i) magnetic core having one or more magnetic metal oxide crystals; and
(ii) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals.
2. The nanoparticle of claim 1 wherein reactive primary amino groups are associated with polymer through a peptidyl linkage of the formula:
—O—(CH2)m—CONH—[X]
wherein X is —(CH2)n NH2, —(CH2)oCH NHCOO—, —(CH2)3NH (CH2)4NH2 or —(CH2)3NH(CH2)4NH(CH2)3 NH2—
wherein m=1,2, or 3; n=2,3, 6, and o=3 or 4.
3. The nanoparticle of claim 1 , wherein the magnetic core comprises one or more superparamagnetic iron oxide crystals.
4. The nanoparticle of claim 3 wherein the superparamagnetic core has a diameter between about 1 nm and about 25 nm.
5. The nanoparticle of claim 4 where in the superparamagnetic core has a diameter between about 3 nm and about 10 nm.
6. The nanoparticle of claim 5 wherein the core has a diameter about 5 nm.
7. The nanoparticle of claim 1 wherein the nanoparticle has diameter between about 15 nm and 100 nm.
8. The nanoparticle of claim 7 wherein the nanoparticle has a diameter between about 20 nm and about 100 nm.
9. The nanoparticle of claim 1 wherein the coating is selected from the group of polymers consisting of natural polymers, synthetic polymers and derivatives thereof.
10. The nanoparticle of claim 1 wherein the polymer is carboxymethyldextran.
11. The nanoparticle of claim 1 wherein the nanoparticle is conjugated with a biomolecule.
12. The nanoparticle of claim 11 wherein the biomolecule has at least one sulfhydryl group wherein the sulfhydryl group reacts with an amino group on the coating.
13. A nanoparticle-bioconjugate molecule comprising:
(i) a nanoparticle, the nanoparticle comprising
(a) a magnetic core having one or more magnetic metal oxide crystals;
(b) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals;
(ii) a biomolecule linked to the nanoparticle, wherein the biomolecule has at least one sufhydryl group linked to the amino group.
14. The a nanoparticle-bioconjugate of claim 13 wherein the amino groups are associated with polymer through a peptidyl linkage of the formula:
—O—(CH2)m—CONH—[X]
wherein X is —(CH2)n NH2, —(CH2)oCH NHCOO—, —(CH2)3NH (CH2)4NH2 or —(CH2)3NH(CH2)4NH(CH2)3 NH2
wherein m=1, 2, or 3; n=2, 3, 6, and o=3 or 4.
15. A process for synthesizing an amine functionalized magnetic metal oxide nanoparticle comprising:
i. obtaining a polymer having a plurality of carboxyl groups attached thereto,
ii. contacting the polymer with magnetic metal oxide to produce a coated magnetic metal oxide wherein a portion of the carboxyl groups are associated with the metal oxide;
iii. reacting the coated magnetic metal oxide of step (ii) with a diamine.
16. The process of claim 15 wherein the diamine is ethylene diamine.
17. The process of claim 15 wherein the diamine is hexane diamine.
18. The process of claim 15 wherein step (ii) further comprises the steps of
(a) providing a solution of soluble iron salts;
(b) converting the iron salts into iron oxide crystals; and
(c) removing unassociated polymer.
19. The process of claim 18 wherein the step of converting the iron salts into iron oxides further includes the steps of:
(d) heating the iron salts to a temperature between about 4° C. and about 20° C.;
(e) adding an amount of base to raise the pH to about 8 or higher to form iron oxides.
20. The process of claim 19 further including the step of heating the iron oxides to a temperature about 60° C. or more for at least 30 minutes.
21. A pharmaceutical composition comprising:
(A) A nanoparticle-bioconjugate molecule comprising:
(i) a nanoparticle, the nanoparticle comprising
(a) a magnetic core having one or more magnetic metal oxide crystals;
(b) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals;
(ii) a biomolecule linked to the nanoparticle, wherein the biomolecule has at least one sufhydryl group linked to at least one amino group; and
(B) a pharmaceutically acceptable carrier.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/335,790 US20030124194A1 (en) | 2002-01-02 | 2003-01-02 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
US12/118,020 US8420055B2 (en) | 2002-01-02 | 2008-05-09 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34523302P | 2002-01-02 | 2002-01-02 | |
US10/335,790 US20030124194A1 (en) | 2002-01-02 | 2003-01-02 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/118,020 Continuation US8420055B2 (en) | 2002-01-02 | 2008-05-09 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030124194A1 true US20030124194A1 (en) | 2003-07-03 |
Family
ID=23354146
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/335,790 Abandoned US20030124194A1 (en) | 2002-01-02 | 2003-01-02 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
US12/118,020 Active 2026-05-19 US8420055B2 (en) | 2002-01-02 | 2008-05-09 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/118,020 Active 2026-05-19 US8420055B2 (en) | 2002-01-02 | 2008-05-09 | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
Country Status (5)
Country | Link |
---|---|
US (2) | US20030124194A1 (en) |
EP (1) | EP1469989B1 (en) |
AT (1) | ATE536993T1 (en) |
AU (1) | AU2003207438A1 (en) |
WO (1) | WO2003057175A2 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040106781A1 (en) * | 2002-08-16 | 2004-06-03 | Emrick Todd S. | Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation |
US20050192381A1 (en) * | 2003-07-18 | 2005-09-01 | Bringley Joseph F. | Amine polymer-modified nanoparticulate carriers |
WO2006076636A1 (en) * | 2005-01-14 | 2006-07-20 | Carestream Health, Inc. | Amine polymer-modified nanoparticulate carriers |
US20070140974A1 (en) * | 2005-12-15 | 2007-06-21 | General Electric Company | Targeted nanoparticles for magnetic resonance imaging |
US20080008654A1 (en) * | 2006-07-07 | 2008-01-10 | Boston Scientific Scimed, Inc. | Medical devices having a temporary radiopaque coating |
US20080081192A1 (en) * | 2005-10-14 | 2008-04-03 | Goh Cynthia M | Composite Nanoparticles, Nanoparticles and Methods for Producing Same |
US20080102036A1 (en) * | 2003-06-04 | 2008-05-01 | Poss Kirtland G | Biocompatible Fluorescent Silicon Nanoparticles |
US20080193766A1 (en) * | 2007-02-13 | 2008-08-14 | Northern Nanotechnologies | Control of Transport to and from Nanoparticle Surfaces |
US20080226562A1 (en) * | 2005-12-22 | 2008-09-18 | Kevin Groves | Biocompatible fluorescent metal oxide nanoparticles |
US20080286207A1 (en) * | 2007-02-09 | 2008-11-20 | Visen Medical, Inc. | Polycyclo Dyes and Use Thereof |
US20090068115A1 (en) * | 2002-01-02 | 2009-03-12 | Visen Medical, Inc. | Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor |
US20090182120A1 (en) * | 2005-01-21 | 2009-07-16 | Argylla Technologies, Llp | Surface mediated self-assembly of nanoparticles |
US20090278283A1 (en) * | 2008-05-07 | 2009-11-12 | Northern Nanotechnologies, Inc. | Producing nanoparticles using nanoscale polymer templates |
US20090305247A1 (en) * | 2005-11-30 | 2009-12-10 | Zhiqiang Gao | Nanoparticle and methods therefor |
US20100239864A1 (en) * | 2006-03-27 | 2010-09-23 | Tokyo Institute Of Technology | Method of manufacturing polymer coated ferromagnetic particles and polymer coated ferromagnetic particles |
US8333993B1 (en) | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
US8409463B1 (en) * | 2007-07-16 | 2013-04-02 | University Of Central Florida Research Foundation, Inc. | Aqueous method for making magnetic iron oxide nanoparticles |
WO2014004577A1 (en) | 2012-06-25 | 2014-01-03 | The General Hospital Corporation | Sorting particles using high gradient magnetic fields |
US20140271899A1 (en) * | 2013-03-14 | 2014-09-18 | Peroxyium, Inc., Delaware C Corp. | Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceco2 particles via nano-encapsulation and coating |
US20140342388A1 (en) * | 2013-04-04 | 2014-11-20 | Yang Cai | Reagent for labeling primary amine groups in proteins |
US8945628B2 (en) | 2010-05-26 | 2015-02-03 | The General Hospital Corporation | Magnetic nanoparticles |
US20150079006A1 (en) * | 2012-04-06 | 2015-03-19 | Snu R&Db Foundation | Iron oxide nanocomposite, magnetic resonance imaging t2 contrast medium comprising same, and method for manufacturing same |
WO2015058206A1 (en) | 2013-10-18 | 2015-04-23 | The General Hosptial Corporation | Microfluidic sorting using high gradient magnetic fields |
US20150111303A1 (en) * | 2012-05-08 | 2015-04-23 | Postech Academy-Industry Foundation | Synthesis of molecule on nanoparticle surface for stable detection of nitroaromatic explosives, and sensor using same |
US9057094B1 (en) | 2007-10-25 | 2015-06-16 | University Of Central Florida Research Foundation, Inc. | Nanoparticle-mediated methods for antimicrobial susceptibility testing of bacteria |
US9109249B2 (en) | 2011-05-19 | 2015-08-18 | University Of Central Florida Research Foundation, Inc. | Microbe detection via hybridizing magnetic relaxation nanosensors |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
WO2016073486A1 (en) | 2014-11-03 | 2016-05-12 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US9574085B2 (en) | 2005-09-02 | 2017-02-21 | Visen Medical, Inc. | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels |
US9649389B2 (en) | 2013-03-15 | 2017-05-16 | Visen Medical, Inc. | Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection |
US9897604B2 (en) | 2013-03-15 | 2018-02-20 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
US9958416B2 (en) | 2011-11-23 | 2018-05-01 | The General Hospital Corporation | Analyte detection using magnetic hall effect |
US9999687B2 (en) | 2008-01-18 | 2018-06-19 | Visen Medical, Inc. | Fluorescent imaging agents |
US10221159B2 (en) | 2011-05-09 | 2019-03-05 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
CN112118870A (en) * | 2018-05-08 | 2020-12-22 | 马克斯·普朗克索赔科学公司 | Nanoparticles with non-covalently bound targeting moieties for therapeutic methods and non-medical uses |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797380B2 (en) | 2002-07-31 | 2004-09-28 | General Electric Company | Nanoparticle having an inorganic core |
JP2007505311A (en) * | 2003-09-09 | 2007-03-08 | コニンクリユケ フィリップス エレクトロニクス エヌ.ブイ. | Nanoparticles for detecting analytes |
ES2242528B1 (en) | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | MAGNETIC NANOPARTICLES OF NOBLE METALS. |
EP1721603A1 (en) * | 2005-05-11 | 2006-11-15 | Albert-Ludwigs-Universität Freiburg | Nanoparticles for bioconjugation |
DK1937676T3 (en) * | 2005-09-02 | 2017-03-06 | Visen Medical Inc | Biocompatible fluorescent imaging compounds |
WO2007028118A2 (en) | 2005-09-02 | 2007-03-08 | Visen Medical, Inc. | Nicotinic acid and picolinic acid derived near-infrared fluorophores |
US20090041674A1 (en) * | 2006-02-28 | 2009-02-12 | William Alexander Jones | Targeted iron oxide nanparticles |
JP2009530032A (en) * | 2006-03-21 | 2009-08-27 | アルザ・コーポレーシヨン | Hydratable high molecular weight ester matrix for drug electrotransport |
WO2008109832A2 (en) * | 2007-03-08 | 2008-09-12 | Visen Medical, Inc. | Viable near-infrared fluorochrome labeled cells and methods of making and using same |
US8236284B1 (en) | 2008-04-02 | 2012-08-07 | University Of Central Florida Research Foundation, Inc. | Multimodal, multifunctional polymer coated nanoparticles |
US8324125B2 (en) * | 2009-09-03 | 2012-12-04 | The United States Of America As Represented By The Administrator Of The U.S. Environmental Protection Agency | Magnetic nanoparticle-supported glutathione as a sustainable organocatalyst |
CA2779099C (en) | 2009-10-30 | 2021-08-10 | Northwestern University | Templated nanoconjugates |
CN104245954A (en) | 2012-03-30 | 2014-12-24 | 文森医学公司 | Bacterial imaging agents and methods of using same |
CA2882019C (en) | 2012-08-15 | 2021-02-09 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
CN104297219A (en) * | 2013-07-16 | 2015-01-21 | 上海乐宇生物科技有限公司 | A high-sensitivity triphosadenine detecting method |
EP3143386A4 (en) * | 2014-05-12 | 2017-11-29 | Qi, Huan | Method and system for analyte sensing |
JP2017539080A (en) | 2014-10-23 | 2017-12-28 | コーニング インコーポレイテッド | Polymer encapsulated magnetic nanoparticles |
EP3338806A1 (en) * | 2016-12-21 | 2018-06-27 | Université de Namur | Method for functionalising nanoparticles |
BR112022013206A2 (en) | 2019-12-31 | 2022-09-13 | Univ Santiago Chile | SYSTEM AND METHOD FOR DETECTION OF BIOLOGICAL ANALYTE, WHICH INCLUDES A MICRO-ORGANISM, BY CHANGE IN MAGNETIC PROPERTY OF A SUBSTRATE, WHICH USES SUPERPARAMAGNETIC NANOPARTICLES |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4101435A (en) * | 1975-06-19 | 1978-07-18 | Meito Sangyo Kabushiki Kaisha | Magnetic iron oxide-dextran complex and process for its production |
US4369226A (en) * | 1979-03-19 | 1983-01-18 | California Institute Of Technology | Polyglutaraldehyde synthesis and protein bonding substrates |
US4438239A (en) * | 1981-03-30 | 1984-03-20 | California Institute Of Technology | Microsphere coated substrate containing reactive aldehyde groups |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4654267A (en) * | 1982-04-23 | 1987-03-31 | Sintef | Magnetic polymer particles and process for the preparation thereof |
US5204457A (en) * | 1989-10-20 | 1993-04-20 | Meito Sangyo Kabushiki Kaisha | Organic magnetic complex |
US5395688A (en) * | 1987-10-26 | 1995-03-07 | Baxter Diagnostics Inc. | Magnetically responsive fluorescent polymer particles |
US5424419A (en) * | 1991-06-11 | 1995-06-13 | Meito Sangyo Kabushiki Kaisha | Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide |
US5478576A (en) * | 1986-07-03 | 1995-12-26 | Advanced Magnetics, Inc. | Arabinogalactan derivatives and uses thereof |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
US6074884A (en) * | 1997-10-09 | 2000-06-13 | Coulter International Corp. | Stable protein-nickel particles and methods of production and use thereof |
US6120856A (en) * | 1995-06-07 | 2000-09-19 | Immunivest Corporation | Coated, resuspendable magnetically responsive, transition metal oxide particles and method for the preparation thereof |
US6133047A (en) * | 1996-05-24 | 2000-10-17 | Bio Merieux | Superparamagnetic monodisperse particles |
US6274121B1 (en) * | 1994-07-27 | 2001-08-14 | Herbert Pilgrimm | Superparamagnetic particles, process for their manufacture and use |
US6503762B1 (en) * | 1997-12-25 | 2003-01-07 | Tosoh Corporation | Magnetic carrier, preparation thereof, and method of extraction of nucleic acid |
US6548264B1 (en) * | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
US6767635B1 (en) * | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219335A (en) | 1978-09-18 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Immunochemical testing using tagged reagents |
US4628037A (en) | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
US5569587A (en) | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
US5627027A (en) | 1986-04-18 | 1997-05-06 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
US5262176A (en) | 1986-07-03 | 1993-11-16 | Advanced Magnetics, Inc. | Synthesis of polysaccharide covered superparamagnetic oxide colloids |
US4981977A (en) | 1989-06-09 | 1991-01-01 | Carnegie-Mellon University | Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups |
US5164297A (en) | 1990-05-03 | 1992-11-17 | Advanced Magnetics Inc. | Solvent mediated relaxation assay system |
US5445970A (en) | 1992-03-20 | 1995-08-29 | Abbott Laboratories | Magnetically assisted binding assays using magnetically labeled binding members |
WO1994005203A1 (en) | 1992-09-04 | 1994-03-17 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
US5808044A (en) | 1993-01-22 | 1998-09-15 | Pharmacia Biotech Inc. | Indocarbocyanine and benzindocarbocyanine phosphoramidites |
US6127134A (en) | 1995-04-20 | 2000-10-03 | Carnegie Mellon University | Difference gel electrophoresis using matched multiple dyes |
US5539658A (en) | 1995-05-16 | 1996-07-23 | Minnesota Mining And Manufacturing Company | Electronic presentation system using portable storage media |
US6008373A (en) | 1995-06-07 | 1999-12-28 | Carnegie Mellon University | Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer |
IT1276833B1 (en) | 1995-10-09 | 1997-11-03 | Sorin Biomedica Cardio Spa | FLUORESCENT DYES OF THE SULFUR BENZ AND INDOCYANINE FAMILY |
US6004536A (en) | 1995-11-14 | 1999-12-21 | Molecular Probes, Inc. | Lipophilic cyanine dyes with enchanced aqueous solubilty |
DE69706417T2 (en) | 1996-04-19 | 2002-06-27 | Amersham Pharm Biotech Uk Ltd | SQUARE DYES AND THEIR USE IN A FLUORESCENCE SEQUENCING PROCESS |
US6316265B1 (en) * | 1997-03-13 | 2001-11-13 | Abbott Laboratories | Determination of % glycated hemoglobin |
US5877310A (en) | 1997-04-25 | 1999-03-02 | Carnegie Mellon University | Glycoconjugated fluorescent labeling reagents |
US6248539B1 (en) | 1997-09-05 | 2001-06-19 | The Scripps Research Institute | Porous semiconductor-based optical interferometric sensor |
US6046585A (en) | 1997-11-21 | 2000-04-04 | Quantum Design, Inc. | Method and apparatus for making quantitative measurements of localized accumulations of target particles having magnetic particles bound thereto |
US6133445A (en) | 1997-12-17 | 2000-10-17 | Carnegie Mellon University | Rigidized trimethine cyanine dyes |
EP1078023B1 (en) | 1998-04-08 | 2011-01-05 | Corporation Luminex | Luminescent compounds |
US6002003A (en) | 1998-04-14 | 1999-12-14 | Beckman Instruments, Inc. | Cyanine dye activating group with improved coupling selectivity |
US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
US6599498B1 (en) | 1999-04-09 | 2003-07-29 | Advanced Magnetics, Inc. | Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives |
ATE435262T1 (en) | 1999-07-02 | 2009-07-15 | Visen Medical Inc | FLUORESCENT CYANINE LABELS WITH A SULPHAMIDO BRIDGE |
DE60020584T2 (en) | 1999-09-20 | 2006-04-27 | Fuji Photo Film Co., Ltd., Minami-Ashigara | COMPOUNDS FOR FLUORESCENT LABELING |
US6734000B2 (en) | 2000-10-12 | 2004-05-11 | Regents Of The University Of California | Nanoporous silicon support containing macropores for use as a bioreactor |
US6615063B1 (en) | 2000-11-27 | 2003-09-02 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
EP1209205A1 (en) | 2000-11-28 | 2002-05-29 | Innosense S.r.l. | Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds |
EP1221465A1 (en) | 2001-01-03 | 2002-07-10 | Innosense S.r.l. | Symmetric, monofunctionalised polymethine dyes labelling reagents |
US20030044353A1 (en) | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
AU2002320058A1 (en) * | 2001-06-06 | 2002-12-16 | The General Hspital Corporation | Magnetic-nanoparticle conjugates and methods of use |
SK287806B6 (en) | 2001-06-28 | 2011-10-04 | Pfizer Products Inc. | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MPT) and/or apoliprotein B (APO B) secretion |
US7463615B2 (en) | 2001-07-13 | 2008-12-09 | Qualcomm, Incorporated | System and method for extended SIP headers for CDMA parameters |
EP1469989B1 (en) | 2002-01-02 | 2011-12-14 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates |
WO2003061711A2 (en) | 2002-01-16 | 2003-07-31 | Visen Medical, Inc. | Chromophore probes for optical imaging |
AU2003225763A1 (en) | 2002-03-11 | 2003-09-29 | Visen Medical, Inc. | Optical imaging probes |
US7189417B2 (en) | 2002-05-01 | 2007-03-13 | The Trustees Of The University Of Pennsylvania | Nanometer-sized carrier medium |
US20060169843A1 (en) | 2002-05-14 | 2006-08-03 | Barrs Chris C | Release connectors (quick release pull tab) |
WO2003102558A1 (en) | 2002-06-04 | 2003-12-11 | Visen Medical, Inc. | Imaging volumes with arbitrary geometries in contact and non-contact tomography |
US7303741B2 (en) | 2002-09-23 | 2007-12-04 | General Electric Company | Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism |
AU2003303954A1 (en) | 2002-10-25 | 2004-10-11 | Emory University | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
US20080102036A1 (en) | 2003-06-04 | 2008-05-01 | Poss Kirtland G | Biocompatible Fluorescent Silicon Nanoparticles |
WO2005017539A2 (en) | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Imaging pathology |
WO2006010083A2 (en) | 2004-07-08 | 2006-01-26 | Molecular Therapeutics, Inc. | Biodegradable nanoparticles |
EP1787661A1 (en) | 2004-09-10 | 2007-05-23 | Toray Industries, Inc. | Medicinal preparation |
US20070292688A1 (en) | 2005-08-18 | 2007-12-20 | Eastman Kodak Company | Silylamine modified nanoparticulate carriers |
DK1937676T3 (en) | 2005-09-02 | 2017-03-06 | Visen Medical Inc | Biocompatible fluorescent imaging compounds |
AU2006284565B2 (en) | 2005-09-02 | 2013-05-30 | Visen Medical, Inc. | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels |
WO2007028118A2 (en) | 2005-09-02 | 2007-03-08 | Visen Medical, Inc. | Nicotinic acid and picolinic acid derived near-infrared fluorophores |
EP1787659B1 (en) | 2005-11-16 | 2017-03-22 | Exchange Imaging Technologies GmbH | Fluorescent nanoparticles |
US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
-
2003
- 2003-01-02 EP EP03705645A patent/EP1469989B1/en not_active Expired - Lifetime
- 2003-01-02 AT AT03705645T patent/ATE536993T1/en active
- 2003-01-02 AU AU2003207438A patent/AU2003207438A1/en not_active Abandoned
- 2003-01-02 US US10/335,790 patent/US20030124194A1/en not_active Abandoned
- 2003-01-02 WO PCT/US2003/000051 patent/WO2003057175A2/en not_active Application Discontinuation
-
2008
- 2008-05-09 US US12/118,020 patent/US8420055B2/en active Active
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4101435A (en) * | 1975-06-19 | 1978-07-18 | Meito Sangyo Kabushiki Kaisha | Magnetic iron oxide-dextran complex and process for its production |
US4369226A (en) * | 1979-03-19 | 1983-01-18 | California Institute Of Technology | Polyglutaraldehyde synthesis and protein bonding substrates |
US4438239A (en) * | 1981-03-30 | 1984-03-20 | California Institute Of Technology | Microsphere coated substrate containing reactive aldehyde groups |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4654267A (en) * | 1982-04-23 | 1987-03-31 | Sintef | Magnetic polymer particles and process for the preparation thereof |
US5478576A (en) * | 1986-07-03 | 1995-12-26 | Advanced Magnetics, Inc. | Arabinogalactan derivatives and uses thereof |
US5395688A (en) * | 1987-10-26 | 1995-03-07 | Baxter Diagnostics Inc. | Magnetically responsive fluorescent polymer particles |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5204457A (en) * | 1989-10-20 | 1993-04-20 | Meito Sangyo Kabushiki Kaisha | Organic magnetic complex |
US5424419A (en) * | 1991-06-11 | 1995-06-13 | Meito Sangyo Kabushiki Kaisha | Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide |
US6274121B1 (en) * | 1994-07-27 | 2001-08-14 | Herbert Pilgrimm | Superparamagnetic particles, process for their manufacture and use |
US6120856A (en) * | 1995-06-07 | 2000-09-19 | Immunivest Corporation | Coated, resuspendable magnetically responsive, transition metal oxide particles and method for the preparation thereof |
US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
US6133047A (en) * | 1996-05-24 | 2000-10-17 | Bio Merieux | Superparamagnetic monodisperse particles |
US6074884A (en) * | 1997-10-09 | 2000-06-13 | Coulter International Corp. | Stable protein-nickel particles and methods of production and use thereof |
US6503762B1 (en) * | 1997-12-25 | 2003-01-07 | Tosoh Corporation | Magnetic carrier, preparation thereof, and method of extraction of nucleic acid |
US6767635B1 (en) * | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
US6548264B1 (en) * | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
Cited By (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420055B2 (en) | 2002-01-02 | 2013-04-16 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
US20090068115A1 (en) * | 2002-01-02 | 2009-03-12 | Visen Medical, Inc. | Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor |
US20040106781A1 (en) * | 2002-08-16 | 2004-06-03 | Emrick Todd S. | Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation |
US7563507B2 (en) * | 2002-08-16 | 2009-07-21 | University Of Massachusetts | Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation |
US20080102036A1 (en) * | 2003-06-04 | 2008-05-01 | Poss Kirtland G | Biocompatible Fluorescent Silicon Nanoparticles |
US20050192381A1 (en) * | 2003-07-18 | 2005-09-01 | Bringley Joseph F. | Amine polymer-modified nanoparticulate carriers |
US7541017B2 (en) | 2003-07-18 | 2009-06-02 | Carestream Health, Inc. | Amine polymer-modified nanoparticulate carriers |
US20080241266A1 (en) * | 2005-01-14 | 2008-10-02 | Bringley Joseph F | Amine polymer-modified nanoparticulate carriers |
WO2006076636A1 (en) * | 2005-01-14 | 2006-07-20 | Carestream Health, Inc. | Amine polymer-modified nanoparticulate carriers |
US20060293396A1 (en) * | 2005-01-14 | 2006-12-28 | Eastman Kodak Company | Amine polymer-modified nanoparticulate carriers |
US8288169B2 (en) * | 2005-01-21 | 2012-10-16 | Argylla Technologies | Surface mediated self-assembly of nanoparticles |
US20090182120A1 (en) * | 2005-01-21 | 2009-07-16 | Argylla Technologies, Llp | Surface mediated self-assembly of nanoparticles |
US9574085B2 (en) | 2005-09-02 | 2017-02-21 | Visen Medical, Inc. | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels |
US10442930B2 (en) | 2005-09-02 | 2019-10-15 | Visen Medical, Inc. | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels |
US20100137474A1 (en) * | 2005-10-14 | 2010-06-03 | Northern Nanotechnologies | Composite Nanoparticles, Nanoparticles and Methods for Producing Same |
US8182867B2 (en) | 2005-10-14 | 2012-05-22 | Vive Crop Protection | Producing composite nanoparticles containing organic ions |
US7964277B2 (en) | 2005-10-14 | 2011-06-21 | Vive Nano, Inc. | Composite nanoparticles, nanoparticles and methods for producing same |
US20090148703A1 (en) * | 2005-10-14 | 2009-06-11 | Northern Nanotechnologies, Inc. | Composite nanoparticles, nanoparticles and methods for producing same |
US7534490B1 (en) | 2005-10-14 | 2009-05-19 | Northern Nanotechnologies, Inc. | Composite nanoparticles, nanoparticles and methods for producing same |
US20080081192A1 (en) * | 2005-10-14 | 2008-04-03 | Goh Cynthia M | Composite Nanoparticles, Nanoparticles and Methods for Producing Same |
USRE45848E1 (en) | 2005-10-14 | 2016-01-19 | Vive Crop Protection Inc. | Composite nanoparticles, nanoparticles and methods for producing same |
US8003166B2 (en) | 2005-10-14 | 2011-08-23 | Vive Nano, Inc. | Composite nanoparticles, nanoparticles and methods for producing same |
US8283036B2 (en) | 2005-10-14 | 2012-10-09 | Vive Crop Protection, Inc. | Composite nanoparticles containing organic ions |
US8257785B2 (en) | 2005-10-14 | 2012-09-04 | Vive Crop Protection, Inc. | Producing composite nanoparticles |
US20090305247A1 (en) * | 2005-11-30 | 2009-12-10 | Zhiqiang Gao | Nanoparticle and methods therefor |
US20070140974A1 (en) * | 2005-12-15 | 2007-06-21 | General Electric Company | Targeted nanoparticles for magnetic resonance imaging |
US20080226562A1 (en) * | 2005-12-22 | 2008-09-18 | Kevin Groves | Biocompatible fluorescent metal oxide nanoparticles |
US9913917B2 (en) * | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US20100239864A1 (en) * | 2006-03-27 | 2010-09-23 | Tokyo Institute Of Technology | Method of manufacturing polymer coated ferromagnetic particles and polymer coated ferromagnetic particles |
US20080008654A1 (en) * | 2006-07-07 | 2008-01-10 | Boston Scientific Scimed, Inc. | Medical devices having a temporary radiopaque coating |
US8333993B1 (en) | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
US20080286207A1 (en) * | 2007-02-09 | 2008-11-20 | Visen Medical, Inc. | Polycyclo Dyes and Use Thereof |
US8221721B2 (en) | 2007-02-09 | 2012-07-17 | Visen Medical, Inc. | Polycyclo dyes and use thereof |
US9365721B2 (en) | 2007-02-09 | 2016-06-14 | Visen Medical, Inc. | Polycyclo dyes and use thereof |
US7501180B2 (en) | 2007-02-13 | 2009-03-10 | Northern Nanotechnologies | Nanoparticles confined in polyelectrolytes |
US20080199700A1 (en) * | 2007-02-13 | 2008-08-21 | Northern Nanotechnologies, Inc. | Nanoparticles confined in polyelectrolytes |
US20080193766A1 (en) * | 2007-02-13 | 2008-08-14 | Northern Nanotechnologies | Control of Transport to and from Nanoparticle Surfaces |
US8821837B2 (en) | 2007-07-16 | 2014-09-02 | University Of Central Florida Research Foundation, Inc. | Aqueous method of making magnetic iron oxide nanoparticles |
US8409463B1 (en) * | 2007-07-16 | 2013-04-02 | University Of Central Florida Research Foundation, Inc. | Aqueous method for making magnetic iron oxide nanoparticles |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
US9125941B2 (en) | 2007-07-16 | 2015-09-08 | University Of Central Florida Research Foundation, Inc. | Aqueous method for making magnetic iron oxide nanoparticles |
US9057094B1 (en) | 2007-10-25 | 2015-06-16 | University Of Central Florida Research Foundation, Inc. | Nanoparticle-mediated methods for antimicrobial susceptibility testing of bacteria |
US9999687B2 (en) | 2008-01-18 | 2018-06-19 | Visen Medical, Inc. | Fluorescent imaging agents |
US7967890B2 (en) | 2008-05-07 | 2011-06-28 | Vive Nano, Inc. | Producing nanoparticles using nanoscale polymer templates |
US20100148398A1 (en) * | 2008-05-07 | 2010-06-17 | Vive Nano, Inc. | Producing nanoparticles using nanoscale polymer templates |
US7645318B2 (en) | 2008-05-07 | 2010-01-12 | Vive Nano, Inc. | Producing nanoparticles using nanoscale polymer templates |
US20090278283A1 (en) * | 2008-05-07 | 2009-11-12 | Northern Nanotechnologies, Inc. | Producing nanoparticles using nanoscale polymer templates |
US10111971B2 (en) | 2010-05-26 | 2018-10-30 | The General Hospital Corporation | Magnetic nanoparticles |
US8945628B2 (en) | 2010-05-26 | 2015-02-03 | The General Hospital Corporation | Magnetic nanoparticles |
US9623126B2 (en) | 2010-05-26 | 2017-04-18 | The General Hospital Corporation | Magnetic nanoparticles |
US11059802B2 (en) | 2011-05-09 | 2021-07-13 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
US10221159B2 (en) | 2011-05-09 | 2019-03-05 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
US9109249B2 (en) | 2011-05-19 | 2015-08-18 | University Of Central Florida Research Foundation, Inc. | Microbe detection via hybridizing magnetic relaxation nanosensors |
US9958416B2 (en) | 2011-11-23 | 2018-05-01 | The General Hospital Corporation | Analyte detection using magnetic hall effect |
US20150079006A1 (en) * | 2012-04-06 | 2015-03-19 | Snu R&Db Foundation | Iron oxide nanocomposite, magnetic resonance imaging t2 contrast medium comprising same, and method for manufacturing same |
US20150111303A1 (en) * | 2012-05-08 | 2015-04-23 | Postech Academy-Industry Foundation | Synthesis of molecule on nanoparticle surface for stable detection of nitroaromatic explosives, and sensor using same |
US9878327B2 (en) | 2012-06-25 | 2018-01-30 | The General Hospital Corporation | Sorting particles using high gradient magnetic fields |
US9278353B2 (en) | 2012-06-25 | 2016-03-08 | The General Hospital Corporation | Sorting particles using high gradient magnetic fields |
WO2014004577A1 (en) | 2012-06-25 | 2014-01-03 | The General Hospital Corporation | Sorting particles using high gradient magnetic fields |
US10668470B2 (en) | 2012-06-25 | 2020-06-02 | The General Hospital Corporation | Sorting particles using high gradient magnetic fields |
US20140271899A1 (en) * | 2013-03-14 | 2014-09-18 | Peroxyium, Inc., Delaware C Corp. | Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceco2 particles via nano-encapsulation and coating |
US11193932B2 (en) | 2013-03-15 | 2021-12-07 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
US9649389B2 (en) | 2013-03-15 | 2017-05-16 | Visen Medical, Inc. | Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection |
US10473658B2 (en) | 2013-03-15 | 2019-11-12 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
US9897604B2 (en) | 2013-03-15 | 2018-02-20 | Visen Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
US20140342388A1 (en) * | 2013-04-04 | 2014-11-20 | Yang Cai | Reagent for labeling primary amine groups in proteins |
WO2015058206A1 (en) | 2013-10-18 | 2015-04-23 | The General Hosptial Corporation | Microfluidic sorting using high gradient magnetic fields |
US10202577B2 (en) | 2013-10-18 | 2019-02-12 | The General Hospital Corporation | Microfluidic sorting using high gradient magnetic fields |
US11155779B2 (en) | 2013-10-18 | 2021-10-26 | The General Hospital Corporation | Microfluidic sorting with high gradient magnetic fields using opposing arrays of adjacent magnets |
US11725180B2 (en) | 2013-10-18 | 2023-08-15 | The General Hospital Corporation | Microfluidic sorting using high gradient magnetic fields |
EP3560591A1 (en) | 2013-10-18 | 2019-10-30 | The General Hospital Corporation | Microfluidic sorting using high gradient magnetic fields |
US10150116B2 (en) | 2014-11-03 | 2018-12-11 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US10478819B2 (en) | 2014-11-03 | 2019-11-19 | The General Hospital Corporation | Sorting particles in a microfluidic device |
EP3745139A1 (en) | 2014-11-03 | 2020-12-02 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US11944972B2 (en) | 2014-11-03 | 2024-04-02 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US10875021B2 (en) | 2014-11-03 | 2020-12-29 | The General Hospital Corporation | Sorting particles in a microfluidic device |
US11027280B2 (en) | 2014-11-03 | 2021-06-08 | The General Hospital Corporation | Sorting particles in a microfluidic device |
US11052393B2 (en) | 2014-11-03 | 2021-07-06 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US10583438B2 (en) | 2014-11-03 | 2020-03-10 | The General Hospital Corporation | Combined sorting and concentrating particles in a microfluidic device |
WO2016073486A1 (en) | 2014-11-03 | 2016-05-12 | The General Hospital Corporation | Concentrating particles in a microfluidic device |
US9610582B2 (en) | 2014-11-03 | 2017-04-04 | The General Hospital Corporation | Combined sorting and concentrating particles in a microfluidic device |
US11446664B2 (en) | 2014-11-03 | 2022-09-20 | The General Hospital Corporation | Combined sorting and concentrating particles in a microfluidic device |
US9895694B2 (en) | 2014-11-03 | 2018-02-20 | The General Hospital Corporation | Sorting particles in a microfluidic device |
US11944971B2 (en) | 2014-11-03 | 2024-04-02 | The General Hospital Corporation | Sorting particles in a microfluidic device |
CN112118870A (en) * | 2018-05-08 | 2020-12-22 | 马克斯·普朗克索赔科学公司 | Nanoparticles with non-covalently bound targeting moieties for therapeutic methods and non-medical uses |
Also Published As
Publication number | Publication date |
---|---|
US8420055B2 (en) | 2013-04-16 |
AU2003207438A8 (en) | 2003-07-24 |
EP1469989B1 (en) | 2011-12-14 |
ATE536993T1 (en) | 2011-12-15 |
WO2003057175A2 (en) | 2003-07-17 |
EP1469989A4 (en) | 2006-07-05 |
WO2003057175A3 (en) | 2003-11-13 |
AU2003207438A1 (en) | 2003-07-24 |
US20090068115A1 (en) | 2009-03-12 |
EP1469989A2 (en) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8420055B2 (en) | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor | |
Bae et al. | Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T 1-and T 2-weighted magnetic resonance imaging | |
US10111971B2 (en) | Magnetic nanoparticles | |
Taghavi Pourianazar et al. | Bioapplications of poly (amidoamine)(PAMAM) dendrimers in nanomedicine | |
Aulenta et al. | Dendrimers: a new class of nanoscopic containers and delivery devices | |
Gu et al. | Nuclear penetration of surface functionalized gold nanoparticles | |
US20120107246A1 (en) | Methotrexate-modified nanoparticles and related methods | |
US7976825B2 (en) | Cancer cell diagnosis by targeting delivery of nanodevices | |
Darras et al. | Chitosan modified with gadolinium diethylenetriaminepentaacetic acid for magnetic resonance imaging of DNA/chitosan nanoparticles | |
JPH10512617A (en) | Targeted magnetic labeling molecular marker system for NMR imaging | |
El-Dakdouki et al. | A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging | |
WO2007097605A1 (en) | Water-soluble magnetic or metal oxide nanoparticles coated with ligands, preparation method and usage thereof | |
NO314785B1 (en) | Ferrous double-coated nanoparticles and their use in diagnostics and therapy | |
TW201113040A (en) | Folic acid-mediated magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications | |
Yang et al. | Poly (amino acid)-coated iron oxide nanoparticles as ultra-small magnetic resonance probes | |
US20090041674A1 (en) | Targeted iron oxide nanparticles | |
JP5350257B2 (en) | Imaging of activated vascular endothelium using immunomagnetic MRI contrast agents | |
TW588018B (en) | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof | |
ES2903387T3 (en) | Biocompatible magnetic materials | |
Tian et al. | Targeted solid lipid nanoparticles with peptide ligand for oral delivery of atorvastatin calcium | |
TW201114437A (en) | Magnetic nanoparticles for magnetic resonace imaging | |
Rezayan et al. | A modified PEG-Fe3O4 magnetic nanoparticles conjugated with D (+) glucosamine (DG): MRI contrast agent | |
JP7125725B2 (en) | Amphiphilic polymer nanomicelle containing poly 3,4-dihydroxy-L-phenylalanine chelate ferric ion and use thereof | |
JP4579683B2 (en) | Method for cell labeling with paramagnetic complexes for MRI applications | |
Kracíková et al. | Polymer-colloidal systems as MRI-detectable nanocarriers for peptide vaccine delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VISEN MEDICAL, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GAW, DEBRA A.;JOSEPHSON, LEE;REEL/FRAME:013861/0982 Effective date: 20030311 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |